mainnoe
targeting cell migration in chronic inflammation

Project no. LHSG-CT-2003-502935

Project acronym: MAIN

Project title: Targeting Cell Migration In Chronic Inflammation

Instrument: Network of Excellence

Thematic Priority: **1.1.5**: *Multidisciplinary functional genomics approaches to basic biological processes.*

Final Activity Report

Period covered: from January 1st, 2004 to: December 31st, 2008

Date of preparation: February 29th, 2009

Start date of project: January 1st, 2004 **Duration**: 4 years + 1 year extension

Project coordinator name:
Ruggero Pardi, MD

Project coordinator organisation name:
Fondazione Centro San Raffaele del Monte Tabor, Milan IT (FCSR)

Contents index

Publishable Final Activity Report

Project Execution

Chronic inflammation is a prototypic systemic disorder resulting from the dysregulation of multiple, mechanistically unrelated higher order biological processes. In chronic inflammatory diseases a variety of "inputs" effect the recruitment and activation of immune and inflammatory cells to the site of lesions, thereby amplifying and perpetuating the inflammatory state. The underlying idea of this **five-year** proposal was that the most effective strategy to overcome barriers to progress in chronic inflammation is to promote the synergistic interaction of scientists from many disciplines to challenge the aforementioned processes using a reductionist approach. Based on the above assumptions, this Consotium has gathered 13 research Institutes, 2 SME, 48 research groups, 186 researchers and 91 students with outstanding records or promise of research accomplishments, to focus this project on achieving a thorough understanding of a key basic process in chronic inflammation, namely **directed inflammatory cell migration towards and across injured tissues**. The MAIN Consortium aimed at promoting the integration of multi-disciplinary research groups to achieve a thorough understanding of directed inflammatory cell migration towards and across injured tissues. To achieve its goals, MAIN was based on four developmental Research Programs (Tool Development Program, Target Identification Program, Target Validation Program and Drug Development Program) and one Core Facility (Bioinformatics). The Research Programs were tightly interconnected in a logical sequence of highly integrated activities. The Tool Development Program (TDP) has developed technological tools that are instrumental to make advancements in the field of cell migration as pertains to imaging, proteomics and RNA interference. The Target Identification Program (TIP) identified signaling pathways and/or molecular networks involved in defined aspects of inflammatory cell migration. The Target Validation Program (TVP) has validated targets emerging from the TIP by testing them across in vitro and in vivo models, different inducing stimuli and manipulating conditions. The Drug Development Program (DDP) has focused on developing high content, high throughput assays amenable to test compound libraries. Tools developed by the TDP (Imaging, Microarrays and Proteomics) and the Bioinformatics Core provided technological and biocomputational support to the programs. To spread excellence through education and training, MAIN has implemented a Training and Education Program (TEP), with practical courses and workshops for graduate students and technicians.

As described in the original proposal, the underlying strategy of MAIN was to progressively focus its goals and to emphasize cost-effectiveness of the JPA by restraining the number of initiatives and proportionally increase funding per initiative. To this aim, the initial round of funded initiatives (a total of 33 WP) has been conditionally approved for two years and only under special circumstances such initiatives have been extended for a third year. Otherwise, a second set of WP (4 in total) has been launched towards the end of the 2nd year. This second set of WP was both aiming at refining validation of targets identified in the first round on initiatives and at promoting further integration by fostering new collaborations and mergers of pre-existing WP. The new set of WP has become fully operational during the third year and progress has been reported during the third annual meeting, which has been held in Madrid on October 18th through 20th, 2007. A final set of WP has been approved at the end of the third year as part of the Drug Development Program (Table 3) and has required an amendment to the Contract to extend the duration of MAIN until December 31st, 2008. As an overall indicator of the progressive integration of the Consortium's JPA, the average number of groups per WP increased from 2.5 in the first round of WP to over 3.8 in the second round.



Table 1: time table and interdependencies of the various Programs comprising the MAIN NoE.

Dissemination and use

The MAIN web site and the cost-effective internet-based videoconference system (www.marratech.com) have been constantly updated and made more versatile and effective. As part of the integrating activities, the Bioinformatics Core has fully developed the "integrated inflammation and migration knowledge-database" (MAIN DB). The database comprises several interdependent sections: a Tool database section, accessible to MAIN members, contains detailed descriptions of the tools generated through the Consortium activities; the Deliverable database section consists of a comprehensive and annotated list of deliverables and is publicly available. A new category has been added to the database in early 2007, referring to technical "tutorials" offered by MAIN laboratories to junior members and aimed at fostering mobility and integration. The deliverable database is updated by individual investigators on a six-monthly basis. Further, the MAIN Bioinformatics core has continued developing the pSTIING (Protein, Signalling, Transcriptional Interactions & Inflammation Networks Gateway) relational database. pSTIING is a publicly accessible knowledgebase about protein-protein, protein-lipid, protein-small molecules, ligand-receptor interactions, receptor-cell type information, transcriptional regulatory and signal transduction modules relevant to inflammation and cell migration. The Training and Education Program has been implemented by establishing a consolidated connection with the existing graduate programs in the participating Institutions. MAIN member students have privileged access to the ongoing educational activities (courses, meetings, one day events, etc.) of the Consortium partners' higher education programs through extensive advertising and on-line registration/application forms provided by the MAIN web site. Further, the TEP has been developed through the implementation of short-term tutorials, mostly dealing with state of the art technologies in the field of cell migration, to be accessed by graduate students and junior fellows through the deliverable section of the MAIN data base and to be covered financially by the Consortium. The third MAIN students' retreat, entirely devoted to MAIN graduate students, has taken place in Villars Sur Ollon, CH on May, 19th to 22nd, 2007 with over 50 students

representative of the participating Institutions. Further, a subset of MAIN partners (4 academic sites from IT, ES, UK and CH and 1 SME from IT) has recently been awarded an EST (Early Stage Research Training) proposal aimed at creating a truly international PhD program in Molecular Medicine (Acronym: INTEGRAMM, www.integramm.org), which is entirely based on the premises offered by MAIN for higher education and research training and conforms to the guidelines for higher education in Europe given at the Lisbon (2000) and Bologna (1999) Conferences. INTEGRAMM (MEST-CT-2005-020386) has officially started on April 1st, 2006. The enrolment of long-term and short-term fellows has been completed on March 31st, 2007, leading to the award of 10 three-year fellowships and 3 short-term fellowships. By ending on March 31st, 2010, INTEGRAMM will extend the educational activities patronized by MAIN beyond the duration of the Consortium. Finally, the third MAIN Annual meeting was held in Madrid, ES, on October 18th-20th, 2007. The meeting has been attended by over 90 participants including two members of the External Advisory Board. The meeting provided an ideal setting to appraise progress in the JPA and carefully plan future activities. The event ended with a SC meeting which included a public discussion of the Consortium's status, attended by the EAB members, followed by a restricted meeting of the SC.

Final Plan for Use and Dissemination of Knowledge

Ownership of Knowledge

1. Knowledge shall be the property of the Party generating it.

2. In case several Parties have jointly carried out the work generating Knowledge and the respective share of work cannot be ascertained and put in connection with a specific part of Knowledge, the Parties shall retain the joint ownership of such Knowledge and agree to jointly apply for the new patent application(s), according to each respective intellectual contribution.

3. In case of disagreement about each Party's intellectual contribution, the Parties agree to submit the issue to the Intellectual Property Conciliation Committee, according to par. VI. 6 of this Consortium Agreement.

4. The Parties which are joint owners of Knowledge undertake to sign a co-ownership agreement, which shall specify the applicable arrangements to apply for, to obtain and maintain the relevant patent protection or any other Intellectual Property Rights, to discipline the extension of rights as well as the allocation and assumption of expenses in connection with the protection of Knowledge, and defining the cost sharing and the respective responsibilities for the commercialisation of Knowledge.

5. So long as any such rights are in force, such Parties shall be entitled to use and to license such right on a non-exclusive basis with a financial compensation decided on a case-by-case basis in accordance with the agreements concluded with the prior consent of the other co-owner.

6. Should personnel engaged by a Party in the Project be entitled to claim rights to Knowledge, the Party shall take steps or reach appropriate agreements to ensure that these rights can be exercised in a manner compatible with Party's obligation under the Consortium agreement, the Rules for Participation and the Contract.

7. The partners have agreed that non profit parties may freely transfer ownership of their Knowledge to their technology transfer offices (TTOs), provided that the respective TTOs will be subject to this Consortium Agreement IP requirements. All TTO's offices of the Parties will be listed in Schedule E.

Protection of Knowledge

1. Where Knowledge would be capable of industrial or commercial exploitation, the owning Party shall seek its adequate and effective protection as required by the Consortium agreement, the Contract and the Rules for Participation and having due regard to the legitimate interests of the other Parties.

2. In case the owning Party does not intend to seek adequate and effective protection of its Knowledge, totally or in part, or if it intends to waive such protection, it shall notify to the other Parties through written notice sent to the Coordinator. Such a notification shall take place timely and within a reasonable term in order to allow the Parties to adopt the necessary measures.

3. In the above case, if another Party informs the notifying Party, in writing within 30 (thirty) days of such notice, that it wishes to obtain or maintain the protection of Knowledge, the renouncing Party shall assign to such other Party all necessary rights which it owns. In case more than one Party is willing to obtain or maintain protection of Knowledge and complies with the above specified 30-days term of notice, the notifying Party shall assign jointly the rights on Knowledge to all the Parties which have sent properly and timely their request. Such assignment shall ensure that the Access rights of all Parties will be unaffected.

4. Where the Commission considers it necessary to protect Knowledge in a particular country, and where such protection has not been applied for or has been waived, the Commission may, with the agreement of the Party concerned, adopt protective measures. In this event, and as far as that particular country is concerned, the Community shall take on the obligations regarding the granting of Access rights in lieu of the Party. The Party may only refuse if it can demonstrate that its legitimate interests would be significantly impaired.

5. Each Party would have in place internal policies to adequately protect all patentable results and, in general, the Knowledge.

6. The agreement concluded between the Party and a subcontractor is required:
(i) to prohibit the subcontractor from patenting or from applying for any intellectual property right protection related to the result obtained;
(ii) to transfer the ownership of any result obtained by a subcontractor in the performance of its work; all results belonging to the Party.

Use and dissemination of Knowledge

1. The Parties agree to promote and maximize the dissemination of Knowledge, as long as such dissemination does not impair their rights indicated in the Consortium agreement. The Annex 1 to the Contract describes in detail the foreseen dissemination plan, which includes, among others, the creation of a new web site hosting also a restricted area where Confidential Knowledge will be available to the Parties whilst preserving individual Intellectual Property Rights.

2. Each Party after filing a new patent shall disclose it without delay to the other Parties by submitting it to the Coordinator. The Coordinator will make the new patent available in the restricted area of the web site. The disclosure will be subject to the Confidentiality clause of the Consortium agreement. Starting from the day the patent has been made available in the restricted area of the web site, the other party will have a 90 (ninety) days option right, to undertake a good faith negotiation concerning to such knowledge.. If no license agreement will be signed within 120 (hundred-twenty) days the patent has been made available in the restricted area of the web site, the Party owning Knowledge will be free to commercialise it to Third Parties that are not members in the Consortium, according to the conditions set forth in the following provisions under par. 3.4 of this Chapter.

3. All reagents generated within the project will be made available to the Parties, for research purposes only, under the Material Transfer Agreement, enclosed as Schedule B.
Each Party can transfer such material to Third Parties, by using its own Material Transfer Agreement which shall guarantee the Consortium agreement Access Rights requirements.

Access rights to Third Parties

1. In case the Parties do not exercise their option right as specified in the Consortium Agreement, the Party who owns Knowledge may commercialise it to Third Parties that are not members in the Consortium, according to the conditions set forth in the following provisions.

2. In case a Party transfers the ownership or grants a licence any right to Knowledge, it shall do so according to the relevant provisions of the Consortium agreement, the Contract and the Rules for Participation, with particular regard to the granting of Access rights and the dissemination and use of Knowledge.

3. In case the ownership or any limited right to Knowledge is transferred to a Third Party, the Party shall give prior notice by a certified mail of the content of the proposed assignment and of the name of the proposed assignee to the other Parties of the Project. The Coordinator will inform the Commission of such proposed assignment.

4. Each Party may object within 30 (thirty) days after the receipt of the notification to such a transfer. The Parties may object to any transfer only if this would adversely affect their Access rights. The Commission may object to any transfer of ownership to Third Parties, in particular to those not established in a Member State or an Associated State, if such a transfer is not in accordance with the interests of developing the competitiveness of the dynamic, Knowledge-based European economy, or it is inconsistent with ethical principles.

5. Save the compliance with the aforementioned provisions, each Party may enter into a technical co-operation or licensing arrangement with a Third Parties with regard to its own Knowledge even if there are minor amounts of Knowledge owned by another Party, unavoidably incorporated into or amalgamated with such own Knowledge. Under such circumstances and upon request of the Party entering the co-operation or arrangement, the other Party shall grant non-exclusive rights to permit such co-operation or arrangement base on terms and conditions to be agreed, provided that the grant of such rights does not impair any Legitimate interest of the other Party.

Publications

1. The Parties acknowledge their common interest in publishing Knowledge to obtain recognition and to advance the state of knowledge in the field as set forth in Annex I to the Contract. The Parties also recognise their common interest in obtaining valid intellectual property protection and in protecting business interests.

2. The performance indicators set out in Annex 1 to the Contract state that results arising from collaborative projects within the JPA will be published jointly by the Parties involved. In such a case authorships shall be decided based on academic criteria.
The Parties each separately have the right to publish their own Knowledge.

3. All written or oral public disclosures concerning Knowledge will expressly report that such knowledge has been developed within the Network. Acknowledgement of the EU financial contribution shall be reported as follows: “This work has been supported in part by the EU Network of Excellence “MAIN” (FP6-502935)”.

4. The Party or Parties wishing to make a publication concerning Knowledge developed within the Consortium will provide the other Parties with a copy of the abstract or manuscript and a reasonably detailed description of any oral presentation to the other Parties at the earliest possible

time, but in any event within at least 30 (thirty) days prior to any public disclosure of such Knowledge in whichever format.

Publications mentioning MAIN support, relative to the last reporting period (01.01.2008-31.12.2008)

1. Panattoni M, Sanvito F, Basso V, Doglioni C, Casorati G, Montini E, Bender Jr, Mondino A, Pardi R. (2008). Targeted Inactivation Of The Cop9 Signalosome Impairs Multiple Stages Of T Cell Development. Journal Of Experimental Medicine. Vol. 205, Pp. 465-477.

2. Alfano M, Mariani Sa, Elia C, Pardi R., Blasi F, Poli G. (2008). Ligand-Engaged Urokinase-Type Plasminogen Activator Receptor (Upar) And Activation Of The Cd11b/Cd18 (Mac1) Integrin Inhibit Late Events Of Hiv Expression In Monocytic Cells. Blood. October 21, Ahead Of Print.

3. Cera Mr, Fabbri M, Corada M, Molendini C, Reichel Ca, Krombach F, Pardi R., Dejana E. (2009). Jam-A Promotes Neutrophil Chemotaxis By Controlling Integrin Internalization And Recycling. Journal Of Cell Science. 122: 268-277

4. Molteni R, Lage-Crespo C, Feigelson S, Moser C, Fabbri M, Krombach F, Pardi R. (2009). β-Arrestins Are Required For The Induction And Strengthening Of Shear-Stress Resistant Adhesion During Leukocyte Extravasation. Blood. In Press.

5. Pasvolsky, R., Grabovsky, V., Giagulli, C., Shulman, Z. Shamri, R., Feigelson, S.W. Laudanna, C. and Alon, R. (2008) RhoA is involved in LFA-1 extension triggered by CXCL12 but not in a novel outside-in LFA-1 activation facilitated by CXCL9. J. Immunol. 180, 2815-2823.

6. Shulman, Z., Shinder, V., Klein, E., Grabovsky, V., Yeger, X., Geron, E., Montresor, A.,Bolomini-Vittoi, M., Feigelson, S.W., Kirchhausen, T., Laudanna, C., Shakhar, G. Alon, R., Lymphocyte crawling on and through activated endothelium is mediated by millipede-like contacts generated by chemokine triggered high affinity LFA-1 primed by shear forces. Immunity, In press.

7. Mayor F Jr., Jurado-Pueyo, M., Campos, P.M. and Murga, C. "Interfering with MAP kinase docking interactions: implications and perspective for the p38 route. Cell Cycle 6, 528-533(2007)

8. Rey, M., Valenzuela-Fernández, A., Urzainqui, A., Yáñez-Mó, M., Pérez-Martínez, M., Penela, P., Mayor F Jr., and Sánchez-Madrid, F." Myosin IIA is involved in ligand-induced endocytosis of the chemokine receptor CXCR4" J. Cell. Sci.120, 1126 -1133(2007)

9. Tutor, A., Penela, P., and Mayor F Jr."Anti-beta$_1$ –Adrenergic receptor auto-antibodies are potent stimulators of the ERK1/2 pathway in cardiac cells" Cardiovascular Res. 76, 51-60 (2007)

10. "G protein-coupled receptor kinase 2 (GRK2) positively regulates epithelial cell migration" P.Penela, C. Ribas, I. Aymerich, N. Eijkelkamp, O. Barreiro, C. J.Heijnen, A. Kavelaars , F. Sánchez-Madrid and F. Mayor, jr. EMBO J. 27, 1206-1218 (2008)

11. Penela, P., Murga, C., Ribas, C., Salcedo, A., Jurado-Pueyo, M., Rivas, V., Aymerich. A. and Mayor, F., Jr. "G protein-coupled receptor kinase 2 (GRK2) in migration and inflammation " Arch Physiol Biochem. 114:195-200 (2008)

12. M. Jurado-Pueyo, P.M. Campos, F.Mayor, Jr. and C. Murga "GRK2 desensitization downstream of G proteins" Journal of Receptors and Signal Transduction, 28, 59-70 (2008)

13. Penela, P. and Mayor F Jr."G protein-coupled receptor kinase 2 (GRK2)" Current Biodata-Targeted Proteins Database , www.currentbiodata.com (2008)

14. Penela, P., Ribas, C., Aymerich, I and Mayor F. Jr."New roles of G protein-coupled receptor kinase 2 (GRK2) in cell migration" Cell Adhesión & Migration, 2009, vol. 3 (in press).

15. Woodfin A., Reichel AC., Khandoga A., Corada, M., Voisin M-B., Scheiermann C., Haskard DO., Dejana E., Krombach F. & Nourshargh S. "JAM-A mediates neutrophil transmigration in a stimulus-specific manner in vivo: Evidence for sequential roles for JAM-A and PECAM-1 in neutrophil transmigration". 2007. Blood, 110:1848-1856.

16. Woodfin A., Voisin M-B. & Nourshargh S. "PECAM-1: A multi-functional molecule in inflammation & vascular biology". 2007. Art. Throm. Vasc. Biol., 27: 2514-2523.

17. Woodfin A., Voisin M-B., Engelhardt B. & Nourshargh S. 2009. "Endothelial cell activation leads to neutrophil transmigration as supported by the sequential roles of ICAM-2, JAM-A and PECAM-1". Revised version in preparation for Blood.

18. Mercedes Rey, Agustín Valenzuela-Fernández, Ana Urzainqui, María Yánez-Mó, Manuel Pérez-Martínez, Petronila Penela, Federico Mayor Jr., and Francisco Sánchez-Madrid: "Myosin IIA is envolved in the endocitosis of CXCR4 induced by SDF-1 alpha. J Cell Sci 2007, Mar 15; 120(Pt 6):1126-33. E pub 2007 Feb 27.

19. Olga Barreiro, Hortensia de la Fuente, María Mittelbrunn, and Francisco Sánchez-Madrid: "Functional insights on the polarized redistribution of leukocyte integrins and their ligands during leukocyte migration and immune interactions". Immunol Rev. 2007 Aug; 218:147-64.

20. Ana Urzainqui, Gloria Martínez del Hoyo, Amalia Lamana, Hortensia de la Fuente, Olga Barreiro, Martin K Wild, Dietmar Vestweber, Roberto González Amaro and Francisco Sánchez-Madrid: "Functional role of P-selectin glycoprotein ligand 1/P-selectin interaction in the generation of tolerogenic dendritic cells". J Immunol. 2007 Dec 1;179(11):7457-65.

21. María Yáñez-Mó, Olga Barreiro, Pilar Gonzalo, Alicia Batista, Diego Megías, Laura Genís, Norman Sachs, Mónica Sala-Valdés, Miguel A. Alonso, María C. Montoya, Arnoud Sonnenberg, Alicia G. Arroyo, and Francisco Sánchez-Madrid: "MT1-MMP collagenolytic activity is regulated through association with tetraspanin CD151 in primary endothelial cells". Blood. 2008 Jul 28. Blood. 2008 Oct 15;112(8):3217-26.

22. Olga Barreiro, Moreno Zamai, María Yáñez-Mó, Emilio Tejera, Enrico Gratton, Valeria R. Caiolfa, and Francisco Sánchez-Madrid: "Endothelial adhesion receptors are recruited to adherent leukocytes by inclusion in preformed tetraspanin nanoplatforms". J Cell Biol 2008 Nov 3;183(3):527-42, published online 27 Oct 2008.

23. María Mittelbrunn, Gloria Martínez del Hoyo, María Lopez-Bravo, Noa B. Martín-Cófreces, Alix Scholer, Stéphanie Hugues, Luc Fetler, Sebastián Amigorena, Carlos Ardavín and Francisco Sánchez-Madrid: "Imaging of plasmacytoid dendritic cell interactions with T cells". Blood 2009, 113: 75-84. Prepublished online Sep 25, 2008.

24. Olga Barreiro, Francisco Sánchez-Madrid, María Yánez-Mó. "Live imaging of leukocyte-endothelium interactions". Methods in Molecular Biology, 2009.

25. Olga Barreiro, Río J. Aguilar, Emilio Tejera, Fernando de Torres-Alba, Arturo Evangelista, and Francisco Sánchez-Madrid: "Real Time Imaging of Targeted Microbubbles to Human Endothelium in an ex-vivo model". Under review in JACC Imaging.

26. Birdsey, G.M., Dryden, N.H., Amsellem, V., Gebhardt, F., Sahnan, K., Haskard, D.O., Dejana, E., Mason, J.C., Randi, A.M. The transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood. 2008; 111(7):3498-506.

27. Turowski, P., Martinelli, R., Crawford, R., Wateridge, D., Papageorgiou, A.P., Lampugnani, M.G., Gamp, A.C., Vestweber, D., Adamson, P., Dejana, E., Greenwood, J. Phosphorylation of vascular endothelial cadherin controls lymphocyte emigration. J Cell Sci. 2008;121: 29-37. IF: 6.383

28. Cera MR, Fabbri M, Molendini C, Corada M, Orsenigo F, Rehberg M, Reichel CA, Krombach F, Pardi R, Dejana E. JAM-A promotes neutrophil chemotaxis by controlling integrin internalization and recycling. J Cell Sci. 2009 Jan 15;122(Pt 2):268-77.

29. Cermenati, S., Moleri, S., Cimbro, S., Corti, P., Del Giacco, L., Amodeo, R., Dejana, E., Koopman, P., Cotelli, F., Beltrame, M. Sox18 and Sox7 play redundant roles in vascular development. Blood. 2008; 111:2657-66

30. Rudini, N., Felici, A., Giampietro, C., Lampugnani, M.G., Corada, M., Swirsding, K., Garre', M., Liebner, S., Letarte, M., ten Dijke, P. and Dejana, E. VE-cadherin is a critical endothelial regulator of TGF-beta signalling. EMBO J. 2008 Apr 9;27(7):993-1004.

31. Taddei, A., Giampietro, C., Conti, A., Orsenigo, F., Breviario, F., Pirazzoli, V., Potente, M., Daly, C., Dimmeler, S., Dejana, E. Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol. 2008;10(8):923-34.

32. Liebner S, Corada M, Bangsow T, Babbage J, Taddei A, Czupalla CJ, Reis M, Felici A, Wolburg H, Fruttiger M, Taketo MM, von Melchner H, Plate KH, Gerhardt H, Dejana E. Wnt/beta-catenin signaling controls development of the blood-brain barrier. J Cell Biol. 2008 Nov 3;183(3):409-17.

33. François M, Caprini A, Hosking B, Orsenigo F, Wilhelm D, Browne C, Paavonen K, Karnezis T, Shayan R, Downes M, Davidson T, Tutt D, Cheah KS, Stacker SA, Muscat GE, Achen MG, Dejana E, Koopman P. Sox18 induces development of the lymphatic vasculature in mice. Nature. 2008 Dec 4;456(7222):643-7

34. Nyqvist D, Giampietro C, Dejana E. Deciphering the functional role of endothelial junctions by using in vivo models. EMBO Rep. 2008 Aug;9(8):742-745

35. Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci. 2008 Jul 1;121(Pt 13):2115-22.

36. Vetrano S, Rescigno M, Cera MR, Correale C, Rumio C, Doni A, Fantini M, Sturm A, Borroni E, Repici A, Locati M, Malesci A, Dejana E, Danese S. Unique role of junctional adhesion molecule-A in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology. 2008 Jul;135(1):173-84.

37. Rudini N, Dejana E. Adherens junctions. Curr Biol. 2008 Dec 9;18(23):R1080-2. Zovein AC, Hofmann JJ, Lynch M, French WJ, Turlo KA, Yang Y, Becker MS, Zanetta L, Dejana E, Gasson JC, Tallquist MD, Iruela-Arispe ML. Fate tracing reveals the endothelial origin of hematopoietic stem cells. Cell Stem Cell. 2008 Dec 4;3(6):625-36.

38.

39. Dejana E, Orsenigo F, Molendini C, Baluk P, McDonald DM. Organization and signaling of endothelial cell-to-cell junctions in various regions of the blood and lymphatic vascular trees. Cell Tissue Res. 2009 Jan;335(1):17-25.

40. Flaishon L., Hart G., Zelman E., Moussion C., Grabovsky V., Lapidot Tal G., Feigelson S., Margalit R., Harmelin A., Avin- Wittenberg T., Shoseyov D, Alon R, Girard J.-P. and Shachar I. (2008) "Anti-inflammatory effects of an inflammatory chemokine: CCL2 inhibits lymphocyte homing by modulation of CCL21 triggered integrin-mediated adhesions" Blood 112: 5016-5025.

41. Fougerat, A., Gayral, S., Gourdy, P., Schambourg, A., Ruckle, T., Schwarz, M. K., Rommel, C., Hirsch, E., Arnal, J. F., Salles, J. P., Perret, B., Breton-Douillon, M., Wymann, M. P., and Laffargue, M. (2008). Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. Circulation 117, 1310-1317.

	Workpackage ID	PI	Category	Title
113	WPIFOM20	Giorgio Scita		RNAi screen
115	WPIFOM20	Giorgio Scita		Material exchange
116	WPIFOM20	Giorgio Scita		RNAi screen
118	WPIFOM20	Giorgio Scita		RNAi screen
121	WPIFOM20	Giorgio Scita		RNAi screen
386		Anna Randi		
387		Anna Randi		
389		Anna Randi		
392		Anna Randi		
6	IFOM04	Elisabetta Dejana	Other	Method to measure freshly isolated mouse polymorpphonuclear cell polarization and organization of adhesion proteins.
34	WPFCSR01	Ruggero Pardi	Other	scientific report
35	WPFCSR01	Ruggero Pardi	Other	scientific report
37	WPFCSR01	Ruggero Pardi	Other	MAIN video conference set-up
38	WPFCSR01	Ruggero Pardi	Other	MAIN financial database
39	WPFCSR01	Ruggero Pardi	Other	MAIN WP submission and revision interactive platform
350	WPUMUEN02	Fritz Krombach	Other	Technology for the in vivo study of thrombus formation
357	WPWeizmann01	Steffen Jung	Other	DC and macrophage precursors
390		Anna Randi	Other	
58	WPFCSR02	Francesco Blasi	patents	Immunofluorimetric assay
289	WPUAMAD05	Manuel Fresno Escudero	patents	Possible therapeutic applications in inflammation and tumor migration.
293	WPUAMAD05	Manuel Fresno Escudero	patents	Possible therapeutic applications in inflammation and tumor migration
1	FCSR05	Ruggero Pardi	scientific meetings/workshops	Bioinformatics Information Session/Local Institute Co-Ordinator's Meeting: London, April 7& 8th, 2006
2	FCSR05	Ruggero Pardi	scientific	MAIN Annual Conference, October 6-8th, 2006

			meetings/workshops	
5	FCSR05	Marlene Wolf	scientific meetings/workshops	2nd MAIN PhD Students' Retreat
75	WPFCSR05	Ruggero Pardi	scientific meetings/workshops	First MAIN Annual Conference
78	WPFCSR05	Ruggero Pardi	scientific meetings/workshops	1st MAIN PhD students retreat
79	WPFCSR05	Ruggero Pardi	scientific meetings/workshops	Local Institute Co-Ordinators' Meeting
80	WPFCSR05	Bernhard Moser	scientific meetings/workshops	Plenary lecture at MAIN Student Workshop 2005 in Gwatt, Switzerland
81	WPFCSR05	Marlene Wolf	scientific meetings/workshops	Graduate students retreat
110	WPIFOM20	Buzz Baum	scientific meetings/workshops	Collaborative meeting
120	WPIFOM20	Giorgio Scita	scientific meetings/workshops	Collaborative meeting
123	WPIFOM20	Giorgio Scita	scientific meetings/workshops	Collaborative meeting
145	WPLICR01	Anna Randi	scientific meetings/workshops	Participation to IVBM meeting 6th-10th june 2006
163	WPLICR05	Marketa Zvelebil	scientific meetings/workshops	Bioinformatics tutorial
217	WPUAMAD01	Francisco Sánchez-Madrid	scientific meetings/workshops	Participation in 1st MAIN Annual meeting
219	WPUAMAD01	Francisco Sánchez-Madrid	scientific meetings/workshops	Participation in 1st MAIN PhD students retreat
220	WPUAMAD01	Francisco Sánchez-Madrid	scientific meetings/workshops	Participation in 2nd MAIN PhD students retreat
243	WPUAMAD02	Federico Mayor Menéndez	scientific meetings/workshops	Participation in 1st MAIN PhD students retreat
269	WPUAMAD04	Manuel Ortíz de	scientific	Participation in 1st MAIN PhD students retreat

		Landázuri	meetings/workshops	
274	WPUAMAD04	Manuel Ortíz de Landázuri	scientific meetings/workshops	Participation in 2nd MAIN PhD students retreat
278	WPUAMAD04	Manuel Ortíz de Landázuri	scientific meetings/workshops	Participation in 2nd MAIN Annual meeting
7	IFOM04	Elisabetta Dejana	scientific publications	The transcellular railway: insights into leukocyte diapedesis
12	UMUEN03	Stephan Grabbe	scientific publications	CD40 plus IL-12 and IL-18 is a powerful cocktail for DCα activation and efficiently stimulates antitumoral immunity
13	UMUEN03	Stephan Grabbe	scientific publications	Active Mac-1 (CD11b/CD18) on DC is inhibitory for full T cell activation
15	WPBIOXELL01	Bernhard Moser	scientific publications	Professional Antigen-Presentation Function by HumanT Cells
16	WPBIOXELL01	Bernhard Moser	scientific publications	B cells alter the phenotype and function of follicular-homing CXCR5+ T cells
17	WPBIOXELL01	Bernhard Moser	scientific publications	Cutaneous CXCL14 targets blood precursors to epidermal niches for Langerhans cell differentiation
24	WPBIOXELL01	Daniele D`Ambrosio	scientific publications	FucTVII and lymphocyte recruitment in inflamed brain venules
25	WPBIOXELL01	Daniele D`Ambrosio	scientific publications	Allergen-induced cystitis murine model
44	WPFCSR02	Ruggero Pardi	scientific publications	signal transduction by leukocyte integrins
47	WPFCSR02	Ruggero Pardi	scientific publications	Dynamic partitioning into lipid rafts controls the 2 integrin (LFA-1) during leukocyteβL/αendo-exocytic cycle of the chemotaxis
50	WPFCSR02	Ruggero Pardi	scientific publications	Production of monoclonal antibodies and development of an immunofluorimetric assay specific for the chemotactic epitope of the urokinase receptor
59	WPFCSR02	Francesco Blasi	scientific publications	The urokinase receptor controls cell proliferation in mouse embryonic fibroblasts.
60	WPFCSR02	Francesco Blasi	scientific publications	An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration
61	WPFCSR02	Francesco Blasi	scientific publications	An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration

62	WPFCSR02	Francesco Blasi	scientific publications	Characterization of the hematopoietic stem cell (HSC) mobilization properties of a uPAR Ko mouse.
64	WPFCSR02	Francesco Blasi	scientific publications	Alanine scanning mutagenesis of the urokinase receptor.
90	WPIFOM03	Elisabetta Dejana	scientific publications	The transcellular railway: insights into leukocyte diapedesis.
92	WPIFOM03	Elisabetta Dejana	scientific publications	Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments.
94	WPIFOM03	Elisabetta Dejana	scientific publications	Endothelial cadherins and tumor angiogenesis.
95	WPIFOM03	Elisabetta Dejana	scientific publications	The multiple languages of endothelial cell-to-cell communication.
97	WPIFOM03	Elisabetta Dejana	scientific publications	Generation and characterization of a mouse lymphatic endothelial cell line.
98	WPIFOM03	Elisabetta Dejana	scientific publications	Polymorphonuclear leukocytes diapedesis and recruitment in ischemic and inflammatory sites requires JAM-A expression
99	WPIFOM03	Fritz Krombach	scientific publications	Junctional adhesion molecule-A deficiency increases hepatic ischemia-reperfusion injury despite reduction of neutrophil transendothelial migration
100	WPIFOM03	Hans-Joachim Anders	scientific publications	Junctional adhesion molecule -A deficiency increases hepatic ischemia-reperfusion injury despite reduction of neutrophil transendothelial migration
101	WPIFOM04	Elisabetta Dejana	scientific publications	The role of JAM-A and PECAM-1 in modulating leukocyte infiltration in inflamed and ischemic tissues.
104	WPIFOM04	Dorian Haskard	scientific publications	Collaborative paper on the role of JAM and PECAM in leukocyte infiltration
125	WPIFOM30	Elisabetta Dejana	scientific publications	JAM-A promotes neutrophil chemotaxis by controlling integrin internalization and recycling
126	WPIFOM30	Fritz Krombach	scientific publications	In vivo imaging and quantitative analysis of leukocyte directional migration and polarization in inflamed tissue
127	WPIFOM30	Sussan Nourshargh	scientific publications	Endothelial cell activation leads to neutrophil transmigration as supported by the sequential roles of ICAM-2, JAM-A and PECAM-1
128	WPIFOM30	Sussan Nourshargh	scientific publications	PECAM-1: A multi-functional molecule in inflammation & vascular biology
129	WPIPBS-CNRS01	Jean-Philippe Girard	scientific publications	Cancer cells regulate lymphocyte recruitment and leukocyte-endothelium interactions in the tumor-draining lymph node

132	WPIPBS-CNRS01	Jean-Philippe Girard	scientific publications	IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo
135	WPIPBS-CNRS01	Jean-Philippe Girard	scientific publications	MFPaQ, a new software to parse, validate, and quantify proteomic data generated by ICAT and SILAC mass spectrometric analyses: application to the prot
143	WPLICR01	Bart Vanhaesebroeck	scientific publications	first submitted publication on p110alpha kinase-dead mice
147	WPLICR01	Anna Randi	scientific publications	Endothelial intercellular adhesion molecule (ICAM)-2 regulates angiogenesis.
153	WPLICR02	Buzz Baum	scientific publications	Review article
158	WPLICR05	Marketa Zvelebil	scientific publications	pSTIING: a systems approach towards integrating signalling pathways
165	WPLICR05	Marketa Zvelebil	scientific publications	FLIGHT
166	WPLICR05	Marketa Zvelebil	scientific publications	Resources for integrative systems biology: From data through databases to networks and dynamic system models
168	WPLICR20	Anne Ridley	scientific publications	Role of RhoA in p110delta signalling
171	WPLMU05	Fritz Krombach	scientific publications	Postischemic vascular permeability requires both TLR-2 and TLR-4 but only TLR-2 mediates the transendothelial migration of leukocytes
172	WPLMU05	Fritz Krombach	scientific publications	An orally active chemokine receptor CCR-1 antagonist improves advanced nephropathy in type 2 diabetic db/db mice by blocking interstitial macrophages
173	WPLMU05	Fritz Krombach	scientific publications	Matrix metalloproteinases 2 and 9 promote neutrophil and T cell migration in the postischemic liver
174	WPLMU05	Fritz Krombach	scientific publications	Chemokine receptors Ccr1, Ccr2, and Ccr5 mediate neutrophil migration to postischemic tissue
175	WPLMU05	Fritz Krombach	scientific publications	CD4+ T cells interacting with sinusoidal endothelium and platelets aggravate microvascular hepatic ischemia-reperfusion injury via CD40-CD40L- and ...
176	WPLMU05	Hans-Joachim Anders	scientific publications	Disease mechanisms of glomerulonephritis: chemokines and chemokine receptors.
177	WPLMU05	Hans-Joachim Anders	scientific publications	Chemokines as therapeutic targets in renal disease: Lessons from antagonist studies and knock out mice.

178	WPLMU05	Hans-Joachim Anders	scientific publications	CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome.
179	WPLMU05	Hans-Joachim Anders	scientific publications	Progression of kidney disease: blocking leukocyte recruitment with chemokine receptor CCR1 antagonists.
180	WPLMU05	Hans-Joachim Anders	scientific publications	Molecular mechanisms of autoimmunity triggered by microbial infection.
181	WPLMU05	Hans-Joachim Anders	scientific publications	Progression of kidney disease: blocking leukocyte recruitment with chemokine receptor CCR1 antagonists.
182	WPLMU05	Hans-Joachim Anders	scientific publications	Molecular mechanisms of autoimmunity triggered by microbial infection.
183	WPLMU05	Hans-Joachim Anders	scientific publications	Current paradigms about chemokines as therapeutic targets
184	WPLMU05	Hans-Joachim Anders	scientific publications	Toll-like receptor-7 modulates immune complex glomerulonephritis.
185	WPLMU05	Hans-Joachim Anders	scientific publications	Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells.
186	WPLMU05	Hans-Joachim Anders	scientific publications	Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease.
187	WPLMU05	Hans-Joachim Anders	scientific publications	G-Rich DNA Suppresses Systemic Lupus
188	WPLMU05	Hans-Joachim Anders	scientific publications	Toll-like receptor-4: renal cells and bone marrow cells signal for neutrophil recruitment during pyelonephritis
189	WPLMU05	Hans-Joachim Anders	scientific publications	Crucial role of chemokine receptors for neutrophil migration in postischemic tissue in vivo
190	WPLMU05	Hans-Joachim Anders	scientific publications	Targeting the chemokine network in renal inflammation.
211	WPUAMAD01	Francisco Sánchez-Madrid	scientific publications	Association of MT1-MMP with tetraspanin CD151 at endothelial lateral junctions regulates its enzymatic activity
213	WPUAMAD01	Francisco Sánchez-Madrid	scientific publications	Endothelial tetraspanin microdomains regulate leukocyte firm adhesion during extravasation.
214	WPUAMAD01	Francisco	scientific publications	EWI-2 and EWI-F link the tetraspanin web to the actin cytoskeleton

		Sánchez-Madrid		through their direct association with ezrin-radixin-moesin proteins.
226	WPUAMAD01	Francisco Sánchez-Madrid	scientific publications	Endothelial tetraspanin microdomains regulate leukocyte firm adhesion during extravasation.
227	WPUAMAD01	Francisco Sánchez-Madrid	scientific publications	EWI-2 and EWI-F link the tetraspanin web to the actin cytoskeleton through their direct association with ezrin-radixin-moesin proteins.
234	WPUAMAD02	Federico Mayor Menéndez	scientific publications	G protein -coupled receptor kinase 2
236	WPUAMAD02	Federico Mayor Menéndez	scientific publications	Myosin II is involved in ligand-induced internalization of the chemokine receptor CXCR4
239	WPUAMAD02	Federico Mayor Menéndez	scientific publications	Modulation of the interaction between GRK2 and GIT-1
268	WPUAMAD04	Manuel Ortíz de Landázuri	scientific publications	Role of the hypoxia in the macrophage activation.
270	WPUAMAD04	Manuel Ortíz de Landázuri	scientific publications	Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene.
272	WPUAMAD04	Manuel Ortíz de Landázuri	scientific publications	Analysis of HIF-prolyl hydroxylases binding to substrates
276	WPUAMAD04	Manuel Ortíz de Landázuri	scientific publications	von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-in
277	WPUAMAD04	Manuel Ortíz de Landázuri	scientific publications	Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene
280	WPUAMAD04	Manuel Ortíz de Landázuri	scientific publications	Activation of HIF-prolyl hydrosilases by R59949, an inhibitor of the diacylglicerol kinase
281	WPUAMAD04	Manuel Ortíz de Landázuri	scientific publications	Activation of HIF-prolyl hydrosilases by R59949, an inhibitor of the diacylglicerol kinase
282	WPUAMAD04	Manuel Ortíz de Landázuri	scientific publications	Von Hippel-Lindau Tumor Supressor Protein Regulates the Assembly of Intercellular Junctions in Renal Cancer Cells through Hypoxia-Inducible Factor-Ind
283	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Expression and function of the nuclear factor of activated T cells in colon carcinoma cells: involvement in the regulation of

				cyclooxygenase-2.
284	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Up-regulation of G Protein-Coupled Receptor Kinase 2 during T cell activation: A potential role in the control of CXCR4 expression
285	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Up-regulation of cyclooxygenase-2 by interleukin-1? in colon carcinoma cells.
287	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Up-regulation of cyclooxygenase-2 by interleukin-1β in colon carcinoma cells.
288	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Peroxisome proliferator-activated receptor alpha agonists inhibit cyclooxygenase 2 and vascular endothelial growth factor transcriptional activation i
290	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Involvement of TNF and NF-kappa B in the transcriptional control of cyclooxygenase-2 expression by IFN-gamma in macrophages
291	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Expression and function of the nuclear factor of activated T cells in colon carcinoma cells: involvement in the regulation of cyclooxygenase-2.
292	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Up-regulation of G Protein-Coupled Receptor Kinase 2 during T cell activation: A potential role in the control of CXCR4 expression. .
294	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Involvement of TNF and NF-kappa B in the transcriptional control of cyclooxygenase-2 expression by IFN-gamma in macrophages.
300	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Peroxisome proliferator-activated receptor alpha agonists inhibit cyclooxygenase 2 and vascular endothelial growth factor transcriptional activation i
320	WPUAMAD20	Federico Mayor Menéndez	scientific publications	
321	WPUAMAD20	Federico Mayor Menéndez	scientific publications	Mdm2 is involved in the ubiquitination and degradation of G protein-coupled receptor kinase 2
322	WPUAMAD20	Federico Mayor Menéndez	scientific publications	Myosin IIA is involved in ligand-induced endocytosis of the chemokine receptor CXCR4.
331	WPUAMAD31	Ruggero Pardi	scientific publications	Pathophysiology of leukocyte-tissue interactions.
337	WPUMUEN01	Volker Gerke	scientific publications	Identification of monocyte gene products
341	WPUMUEN02	Dietmar Vestweber	scientific publications	physiological functions of ESAM as deduced from the analysis of ESAM -/- mice

342	WPUMUEN02	Dietmar Vestweber	scientific publications	ESAM supports neutrophil extravasation, activation of Rho, and VEGF-induced vascular permeability
347	WPUMUEN02	Dietmar Vestweber	scientific publications	A CD99-related antigen on endothelial cells mediates neutrophil, but not lymphocyte extravasation in vivo
349	WPUMUEN02	Fritz Krombach	scientific publications	Leukocyte transmigration in inflamed liver: A role for endothelial cell-selective adhesion molecule
352	WPUMUEN03	Stephan Grabbe	scientific publications	Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral blood leukocyte depletion
356	WPWEIZMANN05	Francoise Cailler Group	scientific publications	See JI (2005) 174:3227-3236
359	WPWeizmann02	Idit Shachar	scientific publications	Tight regulation of IFN-g transcription and secretion in immature and mature B cells by the inhibitory MHC class I receptor, Ly49G2
360	WPWeizmann02	Idit Shachar	scientific publications	Expression of the Chemokine Receptor CCR2 on Immature B cells
362	WPWeizmann04	Ronen Alon	scientific publications	Alpha4beta1-dependent adhesion strengthening under mechanical strain is regulated by paxillin association with the alpha4 cytoplasmic domain
363	WPWeizmann04	Ronen Alon	scientific publications	Lymphocyte arrest on endothelial ICAM-1
364	WPWeizmann04, WPWeizmann05	Ronen Alon	scientific publications	Force as a facilitator of integrin conformational changes during leukocyte arrest on blood vessels and antigen-presenting cells
365	WPWeizmann04, WPWeizmann06	Ronen Alon	scientific publications	Immune cell migration in inflammation
368	WPWeizmann05	Ofer Lider	scientific publications	Enzymattically quiescent heparanase augments T cell interactions with VCAM-1 and extracellular matrix components under versatile dynamic contexts
369	WPWeizmann05	Ofer Lider	scientific publications	Heat shock protein 60 inhibits Th1-mediated hepatitis model via innat regulation of Th1/Th2 transcription factors and cytokines
370	WPWeizmann05	Ofer Lider	scientific publications	Heat shock protein 60 activates cytokine-associated negative regulator suppressor of cytokine signaling 3 in T cells: effects on signaling, chemotaxis
381		Bernhard Moser	scientific publications	Constitutive expression of CXCL14 in healthy human and murine epithelial tissues
382		Bernhard Moser	scientific publications	A rapid crosstalk of human gd T cells and monocytes drives the acute

				inflammation in bacterial infections
383		Marlene Wolf	scientific publications	Proteolytic processing of chemokines: Implications in physiological and pathological conditions
384		Marlene Wolf	scientific publications	Potent and Broad-Spectrum Antimicrobial Activity of CXCL14 Suggests an Immediate Role in Skin Infections
21	WPBIOXELL01	Matthias P. Wymann	Tool, Antibody	p87PIKAP antisera, rabbit & goat
51	WPFCSR02	Ivan de Curtis	Tool, Antibody	SI63 polyclonal antibody
55	WPFCSR02	Ivan de Curtis	Tool, Antibody	SI64 polyclonal antibody
63	WPFCSR02	Francesco Blasi	Tool, Antibody	Antibodies recognizing the chemotactic of the urokinase receptor
111	WPIFOM20	Buzz Baum	Tool, Antibody	Antibody
112	WPIFOM20	Buzz Baum	Tool, Antibody	Phospho-specific antibody
117	WPIFOM20	Giorgio Scita	Tool, Antibody	Antibody
133	WPIPBS-CNRS01	Jean-Philippe Girard	Tool, Antibody	NF-HEV/IL-33 polyclonal antibodies
170	WPLICR20	Anne Ridley	Tool, Antibody	antibodies to p110beta
194	WPLMU06	Judith P. Johnson	Tool, Antibody	Monoclonal anti human CD146 induces signal transduction M18MAD-5D7
195	WPLMU06	Judith P. Johnson	Tool, Antibody	Anti-human MCAM/CD146 monoclonal AB MUC18 IgG2a
199	WPLMU06	Judith P. Johnson	Tool, Antibody	Monoclonal anti human ICAM-1 western blot
203	WPLMU06	Judith P. Johnson	Tool, Antibody	Monoclonal anti human ICAM-1 western blot
208	WPLMU06	Judith P. Johnson	Tool, Antibody	Monoclonal anti human CD146 (MCAM) western blot
233	WPUAMAD02	Ivan de Curtis	Tool, Antibody	Polyclonal antibody specific for GIT proteins
235	WPUAMAD02	Federico Mayor Menéndez	Tool, Antibody	FP1-Ab and FP2-Ab
245	WPUAMAD03	Francisco	Tool, Antibody	TP1/40 Mouse mAb anti-human alphaL integrin (CD11a)

		Sánchez-Madrid		
246	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	LIA1/1 Mouse mAb anti-human CD151
247	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	VJ1/16 Mouse mAb anti-human CD151
248	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	TEA1/41 Mouse mAb, anti-human alpha2 integrin (CD49b).
249	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	RP1/12 Mouse mAb, anti-human CD45RC.
250	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	D3/9 Mouse mAb, anti-human CD45.
251	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	LIA3/2 Mouse mAb anti-human beta-2 integrin (CD18)
253	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	HP2/4 Mouse mAb, anti-human alpha 4 integrin (CD49d)
254	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	HP2/19 Mouse mAb anti-human ICAM-3 (CD50)
255	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	VJ1/6 Mouse mAb, anti-human alpha3 integrin (CD49c).
256	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	HC1/1-B5 Mouse mAb, anti-human Integrin alphaX (CD11c)
257	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	TEA3/9 Mouse mAb, anti-human E-Selectin (CD65E).
258	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	RP1/11 Mouse mAb, anti-human CD45RA
259	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	HP1/7 Mouse mAb, anti-human alpha 4 integrin (CD49d)
260	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	TP1/55 Mouse mAb anti-human CD69
261	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	TP1/55 Mouse mAb anti-human CD69
262	WPUAMAD03	Francisco	Tool, Antibody	HP2/1 Mouse mAb, anti-human alpha 4 integrin (CD49d)

		Sánchez-Madrid		
263	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	TEA1/31 Mouse mAb, anti-human VE-Cadherin.
264	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	RP2/21 Mouse mAb, anti-human CD45RB
265	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	VJ1/10 Mouse mAb, anti-human CD9.
266	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	TP1/15 Mouse mAb, anti-human CD31.
326	WPUAMAD20	Federico Mayor Menéndez	Tool, Antibody	
336	WPUMUEN01	Volker Gerke	Tool, Antibody	Antibodies directed against monocyte gene products
346	WPUMUEN02	Dietmar Vestweber	Tool, Antibody	monoclonal antibodies against mouse ESAM
376	wpifom20	Giorgio Scita	Tool, Antibody	Molecular mechanisms controlling and coordinating the activities of WASP
377	wpifom20	Giorgio Scita	Tool, Antibody	Molecular mechanisms controlling and coordinating the activities of WASP
388		Anna Randi	Tool, Antibody	
391		Anna Randi	Tool, Antibody	
10	PID	Francisco Sánchez-Madrid	Tool, cDNA	7April Deliverable (test)
43	WPFCSR02	Ruggero Pardi	Tool, cDNA	Urokinase receptor cDNA clones
192	WPLMU06	Judith P. Johnson	Tool, cDNA	human CD146 (MCAM) lacking cytoplasmic region; in pcDNA3
196	WPLMU06	Judith P. Johnson	Tool, cDNA	human MCAM full length cDNA (wildtype) in pcDNA3
302	WPUAMAD06	Manuel Fresno Escudero	Tool, cDNA	Human COX-2 Expression plasmid
304	WPUAMAD06	Manuel Fresno Escudero	Tool, cDNA	Human Cyclooxygenase-2 expression plasmid

8	IFOM04	Elisabetta Dejana	Tool, Cell line	Endothelial cell line null for both PECAM and JAM-A
88	WPFCSR30	Ruggero Pardi	Tool, Cell line	Generation of reporter cell lines for primary and secondary screenings of chemotactic compounds
93	WPIFOM03	Elisabetta Dejana	Tool, Cell line	Lines of leukocytes and endothelial cells genetically modified for expression of JAM and its mutants
103	WPIFOM04	Elisabetta Dejana	Tool, Cell line	Lines of leukocytes JAM/PECAM-/-
142	WPLICR01	Bart Vanhaesebroeck	Tool, Cell line	Derivation and characterization of immortalised p110alpha PI3K mutant endothelial cell lines
146	WPLICR01	Anna Randi	Tool, Cell line	MCEC KOICAM2-pBabeIC2
148	WPLICR01	Anna Randi	Tool, Cell line	MCEC KO ICAM2
149	WPLICR01	Anna Randi	Tool, Cell line	MCEC KOICAM2-pBabe
200	WPLMU06	Judith P. Johnson	Tool, Cell line	human SBCl2 melanoma cells stably transfected with MCAM/CD146
204	WPLMU06	Judith P. Johnson	Tool, Cell line	human SBCl2 melanoma cells stably transfected with MCAM/CD146
205	WPLMU06	Judith P. Johnson	Tool, Cell line	Human melanoma cells Mel888 stably transfected with MCAM/CD146 cDNA
206	WPLMU06	Judith P. Johnson	Tool, Cell line	coloncarcinoma Colo320 stably transfected with MCAM/CD146
209	WPLMU06	Judith P. Johnson	Tool, Cell line	293 cells stably transfected with human MCAM/CD146
237	WPUAMAD02	Federico Mayor Menéndez	Tool, Cell line	Hela and Cos
295	WPUAMAD05	Manuel Fresno Escudero	Tool, Cell line	Genetically modified cell lines (Jurkat T COX-2 Tet-on, Jurkat T PGDS Tet-on, THP-1 COX-2 siRNA, THP-1 mPGES-1 siRNA)
299	WPUAMAD05	Manuel Fresno Escudero	Tool, Cell line	Jurkat Tet-on inducible cell line stably transfected with human hematopoietic Prostaglandin D synthase cDNA
345	WPUMUEN02	Dietmar Vestweber	Tool, Cell line	ESAM deficient mouse endothelioma cell lines
14	WPBASEL01	Matthias P. Wymann	Tool, Interfering RNA	shRNA Expression plasmids

52	WPFCSR02	Ivan de Curtis	Tool, Interfering RNA	RNAi to GIT1
53	WPFCSR02	Ivan de Curtis	Tool, Interfering RNA	RNAi to βPIX
136	WPIPBS-CNRS01	Jean-Philippe Girard	Tool, Interfering RNA	NF-HEV/IL-33 siRNAs
155	WPLICR02	Buzz Baum	Tool, Interfering RNA	Human siRNA library for silencing actin regulators.
221	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Interfering RNA	CD151 siRNA
224	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Interfering RNA	CD9 siRNA
229	WPUAMAD02	Ivan de Curtis	Tool, Interfering RNA	Small interfering RNAs to study the effects of GIT1
231	WPUAMAD02	Ivan de Curtis	Tool, Interfering RNA	Small interfering RNAs to study the effects of bPIX
241	WPUAMAD02	Federico Mayor Menéndez	Tool, Interfering RNA	MIIA siRNA
267	WPUAMAD04	Manuel Ortíz de Landázuri	Tool, Interfering RNA	siRNAαHIF-1
273	WPUAMAD04	Manuel Ortíz de Landázuri	Tool, Interfering RNA	PHD3 siRNA
275	WPUAMAD04	Manuel Ortíz de Landázuri	Tool, Interfering RNA	PHD2 siRNA
286	WPUAMAD05	Manuel Fresno Escudero	Tool, Interfering RNA	Development, application and transfer to other MAIN participant groups of siRNA technique on primary leukocytes.
317	WPUAMAD20	Ivan de Curtis	Tool, Interfering RNA	siRNA for rat GIT2 in RBL cells
318	WPUAMAD20	Ivan de Curtis	Tool, Interfering RNA	siRNA for rat PIX proteins in RBL cells
319	WPUAMAD20	Ivan de Curtis	Tool, Interfering RNA	siRNA for rat GIT1 in RBL cells
338	WPUMUEN01	Volker Gerke	Tool, Interfering RNA	RNA interference tools to knock-down monocyte gene products
339	WPUMUEN01	Volker Gerke	Tool, Interfering RNA	siRNA duplexes and constructs to knock-down monocyte gene products
379	wpifom20	Giorgio Scita	Tool, Interfering RNA	Molecular mechanisms controlling and coordinating the activities of WASP
124	WPIFOM20	Giorgio Scita	Tool, other	RNAi screen

154	WPLICR02	Buzz Baum	Tool, other	2 hybrid analysis initiated
49	WPFCSR02	Ruggero Pardi	Tool, Peptide	Cell permeable peptides
65	WPFCSR02	Francesco Blasi	Tool, Peptide	Synthetic peptides
19	WPBIOXELL01	Matthias P. Wymann	Tool, Plasmid	PI3Kgamma plasmid box, extended
23	WPBIOXELL01	Matthias P. Wymann	Tool, Plasmid	p87PIKAP Plasmid-box
54	WPFCSR02	Ivan de Curtis	Tool, Plasmid	Plasmid pEGFP-p95-C
56	WPFCSR02	Ivan de Curtis	Tool, Plasmid	Plasmid pEGFP-p95-C2
57	WPFCSR02	Ivan de Curtis	Tool, Plasmid	Plasmid pEGFP-p95
82	WPFCSR06	Ruggero Pardi	Tool, Plasmid	Tet inducible plasmid vector
89	WPFCSR6	Kenneth B. Marcu	Tool, Plasmid	Developing RNA and protein interference tools to knock-down migration-related genes and proteins
210	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Plasmid	Cyt-pcDNA3/-eGFP/monomeric eGFPΔVCAM-1-
212	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Plasmid	ICAM-1-GFP
215	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Plasmid	VCAM-1-pcDNA3/CFP/YFP/mRFP/monomeric eGFP
216	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Plasmid	CD151-GFP
218	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Plasmid	CD9-CFP/YFP/mRFP/monomeric eGFP
222	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Plasmid	ICAM-1-pcDNA3/CFP/YFP/mRFP/monomeric eGFP
223	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Plasmid	CD81-GFP
225	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Plasmid	CD9-GFP
228	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Plasmid	VCAM-1-pcDNA3/CFP/YFP/mRFP/monomeric eGFP

230	WPUAMAD02	Ivan de Curtis	Tool, Plasmid	Plasmids for the expression in eukaryotes to test the interaction with GRK2
232	WPUAMAD02	Ivan de Curtis	Tool, Plasmid	Plasmid pEGFP-p95-C
240	WPUAMAD02	Federico Mayor Menéndez	Tool, Plasmid	GRK2
242	WPUAMAD02	Federico Mayor Menéndez	Tool, Plasmid	GIT-1
244	WPUAMAD02	Federico Mayor Menéndez	Tool, Plasmid	MIIA tail-GFP
308	WPUAMAD06	Manuel Fresno Escudero	Tool, Plasmid	GAL4-cRel constructs
309	WPUAMAD06	Manuel Fresno Escudero	Tool, Plasmid	GAL4-NFAT constructs
310	WPUAMAD06	Manuel Fresno Escudero	Tool, Plasmid	GAL4-NFATc2 chimeric constructs including deletions of the transactivation domain of human NFATc2
311	WPUAMAD06	Manuel Fresno Escudero	Tool, Plasmid	GAL4-cRel chimeric constructs including deletions of the transactivation domain of c-Rel NF?B
316	WPUAMAD06	Manuel Fresno Escudero	Tool, Plasmid	GAL4-NFATc2 chimeric constructs including deletions of the transactivation domain of human NFATc2
327	WPUAMAD31	Ruggero Pardi	Tool, Plasmid	b2 arrestin Hu 6His P90,92A
328	WPUAMAD31	Ruggero Pardi	Tool, Plasmid	b2 arrestin Hu 6His
329	WPUAMAD31	Ruggero Pardi	Tool, Plasmid	b1 arrestin Hu 6His P89,91A
332	WPUAMAD31	Ruggero Pardi	Tool, Plasmid	b2 arrestin Hu 6His P90,92,95,98A
333	WPUAMAD31	Ruggero Pardi	Tool, Plasmid	b2 arrestin Hu 6His P95,98A
334	WPUAMAD31	Ruggero Pardi	Tool, Plasmid	RalGDS-RBD GST
335	WPUAMAD31	Ruggero Pardi	Tool, Plasmid	b1 arrestin Hu 6His
355	WPUNIBAS01	Matthias P. Wymann	Tool, Plasmid	shRNA expression plasmids, inducible
375	wpifom20	Giorgio Scita	Tool, Plasmid	Molecular mechanisms controlling and coordinating the activities of WASP

33	WPEMBL01	Jochen Wittbrodt	Tool, Promoter	Fugu myeloperoxidase promoter
193	WPLMU06	Judith P. Johnson	Tool, Promoter	Human ICAM-1 luciferase reporter constructs
198	WPLMU06	Judith P. Johnson	Tool, Promoter	human MCAM/CD146 promoter luciferase reporter constructs in pXp2
202	WPLMU06	Judith P. Johnson	Tool, Promoter	human MCAM/CD146 promoter luciferase reporter constructs in pXp2
303	WPUAMAD06	Manuel Fresno Escudero	Tool, Promoter	Mouse Cyclooxygenase-2 promoter deletions and mutants in pxP2 luciferase reporter vector
306	WPUAMAD06	Manuel Fresno Escudero	Tool, Promoter	iNOS promoter
312	WPUAMAD06	Manuel Fresno Escudero	Tool, Promoter	iNOS promoter deletions and mutants in pxP2 and pGL3 luciferase reporter vector
313	WPUAMAD06	Manuel Fresno Escudero	Tool, Promoter	Human COX-2 promoter
314	WPUAMAD06	Manuel Fresno Escudero	Tool, Promoter	Mouse Cyclooxygenase-2 promoter deletions and mutants in pxP2 luciferase reporter vector
315	WPUAMAD06	Manuel Fresno Escudero	Tool, Promoter	mouse COX-2 promoter
372	wPUAMAD06	Manuel Fresno Escudero	Tool, Promoter	Human Cyclooxygenase-2 promoter deletions and mutants in pxP2 luciferase reporter vector
373	wPUAMAD06	Manuel Fresno Escudero	Tool, Promoter	Human Cyclooxygenase-2 promoter deletions and mutants in pxP2 luciferase reporter vector
18	WPBIOXELL01	Matthias P. Wymann	Tool, Protocol/assay	Single cell-based degranulation assay (mixed populations)
20	WPBIOXELL01	Matthias P. Wymann	Tool, Protocol/assay	Mast cell complementation assay (PI3Kgamma pathway)
22	WPBIOXELL01	Matthias P. Wymann	Tool, Protocol/assay	Mast cell complementation assay (PI3Kgamma pathway)
66	WPFCSR02	Matthias P. Wymann	Tool, Protocol/assay	Mast cell migration assay
72	WPFCSR03	Angela Bachi	Tool, Protocol/assay	SILAC method

106	WPIFOM06	Elisabetta Dejana	Tool, Protocol/assay	Centralized collection of protocols
197	WPLMU06	Judith P. Johnson	Tool, Protocol/assay	in vivo angiogenesis assay: the matrigel plug assay
201	WPLMU06	Judith P. Johnson	Tool, Protocol/assay	in vivo angiogenesis assay: the matrigel plug assay
207	WPLMU06	Judith P. Johnson	Tool, Protocol/assay	endothelial tubule formation in vitro
271	WPUAMAD04	Manuel Ortíz de Landázuri	Tool, Protocol/assay	Chromatine Immunoprecipitation (ChIP), used to determine binds to or is localized to a specific DNA sequence in vivo.αwhether HIF-1
330	WPUAMAD31	Ruggero Pardi	Tool, Protocol/assay	Rap1 in vitro activation assay
354	WPUMUEN03	Stephan Grabbe	Tool, Protocol/assay	Purification of murine primary T cells and B cells from spleen and lymph node
36	WPFCSR01	Ruggero Pardi	Tool, Software	MAIN Consortium Web Site
48	WPFCSR02	Ruggero Pardi	Tool, Software	Cell tracker
131	WPIPBS-CNRS01	Jean-Philippe Girard	Tool, Software	MFPaQ, a new software to parse, validate, and quantify proteomic data generated by ICAT and SILAC mass spectrometric analyses
156	WPLICR02	Buzz Baum	Tool, Software	FLIGHT
157	WPLICR05	Marketa Zvelebil	Tool, Software	PHAT
159	WPLICR05	Marketa Zvelebil	Tool, Software	Protein Interaction knowledgebase
160	WPLICR05	Marketa Zvelebil	Tool, Software	Main Resources: Deliverable database
161	WPLICR05	Marketa Zvelebil	Tool, Software	Main Resources: Deliverable database
162	WPLICR05	Marketa Zvelebil	Tool, Software	Main Resources: Tool database
137	WPLICR01	Bart Vanhaesebroeck	Tool, Transgenic animal	constitutive p110alpha kinase-dead (D933A) mice.
140	WPLICR01	Bart Vanhaesebroeck	Tool, Transgenic animal	conditional p110beta mice
144	WPLICR01	Bart Vanhaesebroeck	Tool, Transgenic animal	conditional p110alpha mice
152	WPLICR02	Buzz Baum	Tool, Transgenic animal	GFP flies for in vivo RNAi

167	WPLICR20	Anne Ridley	Tool, Transgenic animal	Mice lacking functional p110beta in monocytes/macrophages
169	WPLICR20	Anne Ridley	Tool, Transgenic animal	Mice with constitutive inactive p110beta
344	WPUMUEN02	Dietmar Vestweber	Tool, Transgenic animal	ESAM deficient mice
353	WPUMUEN03	Stephan Grabbe	Tool, Transgenic animal	OVA-expressing B16 tumor cell line
374	wpifom20	Giorgio Scita	Tool, Transgenic animal	Molecular mechanisms controlling and coordinating the activities of WASP
378	wpifom20	Giorgio Scita	Tool, Transgenic animal	Molecular mechanisms controlling and coordinating the activities of WASP
380	wpifom20	Giorgio Scita	Tool, Transgenic animal	Molecular mechanisms controlling and coordinating the activities of WASP
9	IFOM30	Sussan Nourshargh	Tool, Tutorial	Tutorial: Observation of Confocal Microscopy Approach
11	UMUEN01	Anne Ridley	Tool, Tutorial	Purification and timelapse microscopy of mouse macrophages
76	WPFCSR05	Ruggero Pardi	Tool, Tutorial	Quantitative, single cell time-lapse analysis of directional migration in 2-D chambers
164	WPLICR05	Marketa Zvelebil	Tool, Tutorial	Using MAIN, FLIGHT and pSTIING database
340	WPUMUEN02	Dietmar Vestweber	Tool, Tutorial	Leukocyte cell adhesion and migration assays
343	WPUMUEN02	Dietmar Vestweber	Tool, Tutorial	purification of mouse leukocytes
366	WPWeizmann04; WPWeizmann05	Ronen Alon	Tool, Tutorial	Flow chamber techniques and analyses
367	WPWeizmann04; WPWeizmann05; WPWeizmann06	Ronen Alon	Tool, Tutorial	Leukocyte purification
385		Matthias P. Wymann	Tool, Tutorial	PI3K signaling in immune cells
26	WPEMBL01	Pernille Rorth	Tools	Transgenic Flies

27	WPEMBL01	Pernille Rorth	Tools	Transgenic Flies 2
29	WPEMBL01	Jochen Wittbrodt	Tools	Transgenic medaka expressing nuclear RFP
30	WPEMBL01	Jochen Wittbrodt	Tools	Transgenic Medaka
31	WPEMBL01	Jochen Wittbrodt	Tools	Transgenic medaka expressing GFP
40	WPFCSR02	Ruggero Pardi	Tools	CHO transfectants
41	WPFCSR02	Ruggero Pardi	Tools	Validated siRNA
42	WPFCSR02	Ruggero Pardi	Tools	CHO transfectants expressing WT and mutant aL/b2-GFP chimeric proteins
45	WPFCSR02	Ruggero Pardi	Tools	FP-chimeric constructs
46	WPFCSR02	Ruggero Pardi	Tools	RBL transfectants
67	WPFCSR02	Anne Ridley	Tools	Biosensor Probe for localizing active Cdc42
68	WPFCSR02	Anne Ridley	Tools	interfering RNA to RhoA and RhoB
69	WPFCSR02	Anne Ridley	Tools	Protocol for transfecting T cell leukaemia line
70	WPFCSR02	Anne Ridley	Tools	protocol for analysing T cell polarization and integrin-mediated migration on ICAM-1
71	WPFCSR02	Anne Ridley	Tools	Protocol for transendothelial migration with T cell leukaemia line
83	WPFCSR06	Kenneth B. Marcu	Tools	Validated Murine IKKalpha and IKKbeta shOligos
84	WPFCSR06	Kenneth B. Marcu	Tools	Gateway-Based Retrovector conversion kit
85	WPFCSR06	Kenneth B. Marcu	Tools	Multiple validated Human MMP13 specific shOligos
86	WPFCSR06	Kenneth B. Marcu	Tools	Validated Human IKKalpha and IKKbeta specific shOligos
87	WPFCSR20	Kenneth B. Marcu	Tools	Role of IKK dependent NF-kappaB activation in HMGB1 induced monocyte migration
91	WPIFOM03	Elisabetta Dejana	Tools	Cell lines JAM -/- and +/+ characterized for their interaction with leukocytes
96	WPIFOM03	Elisabetta Dejana	Tools	Genetically modified mice JAM-/- characterized for their properties in different pathological conditions of inflammation or ischemia

				reperfusion
102	WPIFOM04	Elisabetta Dejana	Tools	Genetically modified mice lines JAM/PECAM -/-
105	WPIFOM06	Elisabetta Dejana	Tools	Endothelial lines expressing different mutant proteins relevant in the inflammatory response
107	WPIFOM06	Elisabetta Dejana	Tools	Repository of endothelial cell lines.
108	WPIFOM06	Elisabetta Dejana	Tools	Endothelial lines null for different mutant proteins
109	WPIFOM06	Elisabetta Dejana	Tools	Repository of available cell lines expressing mutant leukocyte adhesion proteins
114	WPIFOM20	Giorgio Scita	Tools	Material exchange
119	WPIFOM20	Giorgio Scita	Tools	Reagent exchange
122	WPIFOM20	Giorgio Scita	Tools	Reagent exchange
130	WPIPBS-CNRS01	Jean-Philippe Girard	Tools	MLV
134	WPIPBS-CNRS01	Jean-Philippe Girard	Tools	HUVEC-NF-HEV
139	WPLICR01	Bart Vanhaesebroeck	Tools	constitutive p110delta kinase-dead (D910A) mice
191	WPLMU06	Judith P. Johnson	Tools	CD146 (MCAM) -/- mice on C57BL/6 and Balb/c backgrounds
296	WPUAMAD05	Manuel Fresno Escudero	Tools	Genetically modified cell lines
298	WPUAMAD05	Manuel Fresno Escudero	Tools	Development, application and transfer to other MAIN participant groups of siRNA technique on primary leukocytes
305	WPUAMAD06	Manuel Fresno Escudero	Tools	Creation of a cDNA expression plasmid repository bank and catalogue
307	WPUAMAD06	Manuel Fresno Escudero	Tools	Creation of a cDNA expression plasmid repository bank and catalogue
324	WPUAMAD20	Federico Mayor Menéndez	Tools	
325	WPUAMAD20	Federico Mayor Menéndez	Tools	

348	WPUMUEN02	Dietmar Vestweber	Tools	Antibodies directed against endothelial cell contact proteins and the corresponding cDNAs
358	WPWeizmann02	Idit Shachar	Tools	Data set of differentially expressed genes in B and T cells following maturation and activation
361	WPWeizmann02	Idit Shachar	Tools	Transgenic animal- CD19-YFP transgenic mice
3	FCSR05	Marlene Wolf	training activities	4th MAIN PhD Students retraet
4	FCSR05	Marlene Wolf	training activities	3rd Graduate Student's retreat
28	WPEMBL01	Pernille Rorth	training activities	Training of imaging in fish
32	WPEMBL01	Jochen Wittbrodt	training activities	Training of collaborators
73	WPFCSR05	Ruggero Pardi	training activities	Tolerance & Autoimmunity
74	WPFCSR05	Ruggero Pardi	training activities	International PhD program in Molecular Medicine
77	WPFCSR05	Ruggero Pardi	training activities	Advanced courses for PhD students
138	WPLICR01	Bart Vanhaesebroeck	training activities	Training of staff in aspects of angiogenesis work
141	WPLICR01	Bart Vanhaesebroeck	training activities	Establishment of techniques to investigate angiogenesis and endothelial migration.
150	WPLICR02	Buzz Baum	training activities	Training in post-genomic biology
151	WPLICR02	Buzz Baum	training activities	EMBO course
238	WPUAMAD02	Federico Mayor Menéndez	training activities	Training in signal transduction imaging and cell migration-related methodologies
252	WPUAMAD03	Francisco Sánchez-Madrid	training activities	Training of a technician in the growth, production and testing of mAbs
279	WPUAMAD04	Manuel Ortíz de Landázuri	training activities	Training of postdoctoral fellow and PhD students in signal transduction, imaging and cell migration-related methodologies
297	WPUAMAD05	Manuel Fresno Escudero	training activities	Training on migration techniques
301	WPUAMAD05	Bernhard Moser	training activities	Training of Alicia Hidalgo
323	WPUAMAD20	Federico Mayor Menéndez	training activities	
351	WPUMUEN03	Stephan Grabbe	training activities	Training for purification of murine primary T and B cells

371	Weizmann01	Steffen Jung	training activities	Isolation and Adoptive Transfer of Mononuclear Phagocyte Precursors

	Workpackage ID	PI	Category	Title
1	FCSR05	Ruggero Pardi	scientific meetings/workshops	Bioinformatics Information Session/Local Institute Co-Ordinator's Meeting: London, April 7& 8th, 2006
2	FCSR05	Ruggero Pardi	scientific meetings/workshops	MAIN Annual Conference, October 6-8th, 2006
3	FCSR05	Marlene Wolf	training activities	4th MAIN PhD Students retraet
4	FCSR05	Marlene Wolf	training activities	3rd Graduate Student's retreat
5	FCSR05	Marlene Wolf	scientific meetings/workshops	2nd MAIN PhD Students' Retreat
6	IFOM04	Elisabetta Dejana	Other	Method to measure freshly isolated mouse polymorpphonuclear cell polarization and organization of adhesion proteins.
7	IFOM04	Elisabetta Dejana	scientific publications	The transcellular railway: insights into leukocyte diapedesis
8	IFOM04	Elisabetta Dejana	Tool, Cell line	Endothelial cell line null for both PECAM and JAM-A
9	IFOM30	Sussan Nourshargh	Tool, Tutorial	Tutorial: Observation of Confocal Microscopy Approach
10	PID	Francisco Sánchez-Madrid	Tool, cDNA	7April Deliverable (test)
11	UMUEN01	Anne Ridley	Tool, Tutorial	Purification and timelapse microscopy of mouse macrophages
12	UMUEN03	Stephan Grabbe	scientific publications	CD40 plus IL-12 and IL-18 is a powerful cocktail for DCα activation and efficiently stimulates antitumoral immunity
13	UMUEN03	Stephan Grabbe	scientific publications	Active Mac-1 (CD11b/CD18) on DC is inhibitory for full T cell activation
14	WPBASEL01	Matthias P. Wymann	Tool, Interfering RNA	shRNA Expression plasmids
15	WPBIOXELL01	Bernhard Moser	scientific publications	Professional Antigen-Presentation Function by HumanT Cells
16	WPBIOXELL01	Bernhard Moser	scientific publications	B cells alter the phenotype and function of follicular-homing CXCR5+ T cells
17	WPBIOXELL01	Bernhard Moser	scientific publications	Cutaneous CXCL14 targets blood precursors to epidermal niches for Langerhans cell differentiation
18	WPBIOXELL01	Matthias P. Wymann	Tool, Protocol/assay	Single cell-based degranulation assay (mixed populations)

19	WPBIOXELL01	Matthias P. Wymann	Tool, Plasmid	PI3Kgamma plasmid box, extended
20	WPBIOXELL01	Matthias P. Wymann	Tool, Protocol/assay	Mast cell complementation assay (PI3Kgamma pathway)
21	WPBIOXELL01	Matthias P. Wymann	Tool, Antibody	p87PIKAP antisera, rabbit & goat
22	WPBIOXELL01	Matthias P. Wymann	Tool, Protocol/assay	Mast cell complementation assay (PI3Kgamma pathway)
23	WPBIOXELL01	Matthias P. Wymann	Tool, Plasmid	p87PIKAP Plasmid-box
24	WPBIOXELL01	Daniele D`Ambrosio	scientific publications	FucTVII and lymphocyte recruitment in inflamed brain venules
25	WPBIOXELL01	Daniele D`Ambrosio	scientific publications	Allergen-induced cystitis murine model
26	WPEMBL01	Pernille Rorth	Tools	Transgenic Flies
27	WPEMBL01	Pernille Rorth	Tools	Transgenic Flies 2
28	WPEMBL01	Pernille Rorth	training activities	Training of imaging in fish
29	WPEMBL01	Jochen Wittbrodt	Tools	Transgenic medaka expressing nuclear RFP
30	WPEMBL01	Jochen Wittbrodt	Tools	Transgenic Medaka
31	WPEMBL01	Jochen Wittbrodt	Tools	Transgenic medaka expressing GFP
32	WPEMBL01	Jochen Wittbrodt	training activities	Training of collaborators
33	WPEMBL01	Jochen Wittbrodt	Tool, Promoter	Fugu myeloperoxidase promoter
34	WPFCSR01	Ruggero Pardi	Other	scientific report
35	WPFCSR01	Ruggero Pardi	Other	scientific report
36	WPFCSR01	Ruggero Pardi	Tool, Software	MAIN Consortium Web Site
37	WPFCSR01	Ruggero Pardi	Other	MAIN video conference set-up
38	WPFCSR01	Ruggero Pardi	Other	MAIN financial database
39	WPFCSR01	Ruggero Pardi	Other	MAIN WP submission and revision interactive platform
40	WPFCSR02	Ruggero Pardi	Tools	CHO transfectants

41	WPFCSR02	Ruggero Pardi	Tools	Validated siRNA
42	WPFCSR02	Ruggero Pardi	Tools	CHO transfectants expressing WT and mutant aL/b2-GFP chimeric proteins
43	WPFCSR02	Ruggero Pardi	Tool, cDNA	Urokinase receptor cDNA clones
44	WPFCSR02	Ruggero Pardi	scientific publications	signal transduction by leukocyte integrins
45	WPFCSR02	Ruggero Pardi	Tools	FP-chimeric constructs
46	WPFCSR02	Ruggero Pardi	Tools	RBL transfectants
47	WPFCSR02	Ruggero Pardi	scientific publications	Dynamic partitioning into lipid rafts controls the 2 integrin (LFA-1) during leukocyteβL/αendo-exocytic cycle of the chemotaxis
48	WPFCSR02	Ruggero Pardi	Tool, Software	Cell tracker
49	WPFCSR02	Ruggero Pardi	Tool, Peptide	Cell permeable peptides
50	WPFCSR02	Ruggero Pardi	scientific publications	Production of monoclonal antibodies and development of an immunofluorimetric assay specific for the chemotactic epitope of the urokinase receptor
51	WPFCSR02	Ivan de Curtis	Tool, Antibody	SI63 polyclonal antibody
52	WPFCSR02	Ivan de Curtis	Tool, Interfering RNA	RNAi to GIT1
53	WPFCSR02	Ivan de Curtis	Tool, Interfering RNA	RNAi to βPIX
54	WPFCSR02	Ivan de Curtis	Tool, Plasmid	Plasmid pEGFP-p95-C
55	WPFCSR02	Ivan de Curtis	Tool, Antibody	SI64 polyclonal antibody
56	WPFCSR02	Ivan de Curtis	Tool, Plasmid	Plasmid pEGFP-p95-C2
57	WPFCSR02	Ivan de Curtis	Tool, Plasmid	Plasmid pEGFP-p95
58	WPFCSR02	Francesco Blasi	patents	Immunofluorimetric assay
59	WPFCSR02	Francesco Blasi	scientific publications	The urokinase receptor controls cell proliferation in mouse embryonic fibroblasts.
60	WPFCSR02	Francesco Blasi	scientific publications	An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration
61	WPFCSR02	Francesco Blasi	scientific publications	An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration
62	WPFCSR02	Francesco Blasi	scientific publications	Characterization of the hematopoietic stem cell (HSC) mobilization

				properties of a uPAR Ko mouse.
63	WPFCSR02	Francesco Blasi	Tool, Antibody	Antibodies recognizing the chemotactic of the urokinase receptor
64	WPFCSR02	Francesco Blasi	scientific publications	Alanine scanning mutagenesis of the urokinase receptor.
65	WPFCSR02	Francesco Blasi	Tool, Peptide	Synthetic peptides
66	WPFCSR02	Matthias P. Wymann	Tool, Protocol/assay	Mast cell migration assay
67	WPFCSR02	Anne Ridley	Tools	Biosensor Probe for localizing active Cdc42
68	WPFCSR02	Anne Ridley	Tools	interfering RNA to RhoA and RhoB
69	WPFCSR02	Anne Ridley	Tools	Protocol for transfecting T cell leukaemia line
70	WPFCSR02	Anne Ridley	Tools	protocol for analysing T cell polarization and integrin-mediated migration on ICAM-1
71	WPFCSR02	Anne Ridley	Tools	Protocol for transendothelial migration with T cell leukaemia line
72	WPFCSR03	Angela Bachi	Tool, Protocol/assay	SILAC method
73	WPFCSR05	Ruggero Pardi	training activities	Tolerance & Autoimmunity
74	WPFCSR05	Ruggero Pardi	training activities	International PhD program in Molecular Medicine
75	WPFCSR05	Ruggero Pardi	scientific meetings/workshops	First MAIN Annual Conference
76	WPFCSR05	Ruggero Pardi	Tool, Tutorial	Quantitative, single cell time-lapse analysis of directional migration in 2-D chambers
77	WPFCSR05	Ruggero Pardi	training activities	Advanced courses for PhD students
78	WPFCSR05	Ruggero Pardi	scientific meetings/workshops	1st MAIN PhD students retreat
79	WPFCSR05	Ruggero Pardi	scientific meetings/workshops	Local Institute Co-Ordinators' Meeting
80	WPFCSR05	Bernhard Moser	scientific meetings/workshops	Plenary lecture at MAIN Student Workshop 2005 in Gwatt, Switzerland
81	WPFCSR05	Marlene Wolf	scientific meetings/workshops	Graduate students retreat
82	WPFCSR06	Ruggero Pardi	Tool, Plasmid	Tet inducible plasmid vector

83	WPFCSR06	Kenneth B. Marcu	Tools	Validated Murine IKKalpha and IKKbeta shOligos
84	WPFCSR06	Kenneth B. Marcu	Tools	Gateway-Based Retrovector conversion kit
85	WPFCSR06	Kenneth B. Marcu	Tools	Multiple validated Human MMP13 specific shOligos
86	WPFCSR06	Kenneth B. Marcu	Tools	Validated Human IKKalpha and IKKbeta specific shOligos
87	WPFCSR20	Kenneth B. Marcu	Tools	Role of IKK dependent NF-kappaB activation in HMGB1 induced monocyte migration
88	WPFCSR30	Ruggero Pardi	Tool, Cell line	Generation of reporter cell lines for primary and secondary screenings of chemotactic compounds
89	WPFCSR6	Kenneth B. Marcu	Tool, Plasmid	Developing RNA and protein interference tools to knock-down migration-related genes and proteins
90	WPIFOM03	Elisabetta Dejana	scientific publications	The transcellular railway: insights into leukocyte diapedesis.
91	WPIFOM03	Elisabetta Dejana	Tools	Cell lines JAM -/- and +/+ characterized for their interaction with leukocytes
92	WPIFOM03	Elisabetta Dejana	scientific publications	Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments.
93	WPIFOM03	Elisabetta Dejana	Tool, Cell line	Lines of leukocytes and endothelial cells genetically modified for expression of JAM and its mutants
94	WPIFOM03	Elisabetta Dejana	scientific publications	Endothelial cadherins and tumor angiogenesis.
95	WPIFOM03	Elisabetta Dejana	scientific publications	The multiple languages of endothelial cell-to-cell communication.
96	WPIFOM03	Elisabetta Dejana	Tools	Genetically modified mice JAM-/- characterized for their properties in different pathological conditions of inflammation or ischemia reperfusion
97	WPIFOM03	Elisabetta Dejana	scientific publications	Generation and characterization of a mouse lymphatic endothelial cell line.
98	WPIFOM03	Elisabetta Dejana	scientific publications	Polymorphonuclear leukocytes diapedesis and recruitment in ischemic and inflammatory sites requires JAM-A expression
99	WPIFOM03	Fritz Krombach	scientific publications	Junctional adhesion molecule-A deficiency increases hepatic ischemia-reperfusion injury despite reduction of neutrophil

				transendothelial migration
100	WPIFOM03	Hans-Joachim Anders	scientific publications	Junctional adhesion molecule -A deficiency increases hepatic ischemia-reperfusion injury despite reduction of neutrophil transendothelial migration
101	WPIFOM04	Elisabetta Dejana	scientific publications	The role of JAM-A and PECAM-1 in modulating leukocyte infiltration in inflamed and ischemic tissues.
102	WPIFOM04	Elisabetta Dejana	Tools	Genetically modified mice lines JAM/PECAM -/-
103	WPIFOM04	Elisabetta Dejana	Tool, Cell line	Lines of leukocytes JAM/PECAM-/-
104	WPIFOM04	Dorian Haskard	scientific publications	Collaborative paper on the role of JAM and PECAM in leukocyte infiltration
105	WPIFOM06	Elisabetta Dejana	Tools	Endothelial lines expressing different mutant proteins relevant in the inflammatory response
106	WPIFOM06	Elisabetta Dejana	Tool, Protocol/assay	Centralized collection of protocols
107	WPIFOM06	Elisabetta Dejana	Tools	Repository of endothelial cell lines.
108	WPIFOM06	Elisabetta Dejana	Tools	Endothelial lines null for different mutant proteins
109	WPIFOM06	Elisabetta Dejana	Tools	Repository of available cell lines expressing mutant leukocyte adhesion proteins
110	WPIFOM20	Buzz Baum	scientific meetings/workshops	Collaborative meeting
111	WPIFOM20	Buzz Baum	Tool, Antibody	Antibody
112	WPIFOM20	Buzz Baum	Tool, Antibody	Phospho-specific antibody
113	WPIFOM20	Giorgio Scita		RNAi screen
114	WPIFOM20	Giorgio Scita	Tools	Material exchange
115	WPIFOM20	Giorgio Scita		Material exchange
116	WPIFOM20	Giorgio Scita		RNAi screen
117	WPIFOM20	Giorgio Scita	Tool, Antibody	Antibody
118	WPIFOM20	Giorgio Scita		RNAi screen
119	WPIFOM20	Giorgio Scita	Tools	Reagent exchange
120	WPIFOM20	Giorgio Scita	scientific	Collaborative meeting

			meetings/workshops	
121	WPIFOM20	Giorgio Scita		RNAi screen
122	WPIFOM20	Giorgio Scita	Tools	Reagent exchange
123	WPIFOM20	Giorgio Scita	scientific meetings/workshops	Collaborative meeting
124	WPIFOM20	Giorgio Scita	Tool, other	RNAi screen
125	WPIFOM30	Elisabetta Dejana	scientific publications	JAM-A promotes neutrophil chemotaxis by controlling integrin internalization and recycling
126	WPIFOM30	Fritz Krombach	scientific publications	In vivo imaging and quantitative analysis of leukocyte directional migration and polarization in inflamed tissue
127	WPIFOM30	Sussan Nourshargh	scientific publications	Endothelial cell activation leads to neutrophil transmigration as supported by the sequential roles of ICAM-2, JAM-A and PECAM-1
128	WPIFOM30	Sussan Nourshargh	scientific publications	PECAM-1: A multi-functional molecule in inflammation & vascular biology
129	WPIPBS-CNRS01	Jean-Philippe Girard	scientific publications	Cancer cells regulate lymphocyte recruitment and leukocyte-endothelium interactions in the tumor-draining lymph node
130	WPIPBS-CNRS01	Jean-Philippe Girard	Tools	MLV
131	WPIPBS-CNRS01	Jean-Philippe Girard	Tool, Software	MFPaQ, a new software to parse, validate, and quantify proteomic data generated by ICAT and SILAC mass spectrometric analyses
132	WPIPBS-CNRS01	Jean-Philippe Girard	scientific publications	IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo
133	WPIPBS-CNRS01	Jean-Philippe Girard	Tool, Antibody	NF-HEV/IL-33 polyclonal antibodies
134	WPIPBS-CNRS01	Jean-Philippe Girard	Tools	HUVEC-NF-HEV
135	WPIPBS-CNRS01	Jean-Philippe Girard	scientific publications	MFPaQ, a new software to parse, validate, and quantify proteomic data generated by ICAT and SILAC mass spectrometric analyses: application to the prot
136	WPIPBS-CNRS01	Jean-Philippe Girard	Tool, Interfering RNA	NF-HEV/IL-33 siRNAs

137	WPLICR01	Bart Vanhaesebroeck	Tool, Transgenic animal	constitutive p110alpha kinase-dead (D933A) mice.
138	WPLICR01	Bart Vanhaesebroeck	training activities	Training of staff in aspects of angiogenesis work
139	WPLICR01	Bart Vanhaesebroeck	Tools	constitutive p110delta kinase-dead (D910A) mice
140	WPLICR01	Bart Vanhaesebroeck	Tool, Transgenic animal	conditional p110beta mice
141	WPLICR01	Bart Vanhaesebroeck	training activities	Establishment of techniques to investigate angiogenesis and endothelial migration.
142	WPLICR01	Bart Vanhaesebroeck	Tool, Cell line	Derivation and characterization of immortalised p110alpha PI3K mutant endothelial cell lines
143	WPLICR01	Bart Vanhaesebroeck	scientific publications	first submitted publication on p110alpha kinase-dead mice
144	WPLICR01	Bart Vanhaesebroeck	Tool, Transgenic animal	conditional p110alpha mice
145	WPLICR01	Anna Randi	scientific meetings/workshops	Participation to IVBM meeting 6th-10th june 2006
146	WPLICR01	Anna Randi	Tool, Cell line	MCEC KOICAM2-pBabeIC2
147	WPLICR01	Anna Randi	scientific publications	Endothelial intercellular adhesion molecule (ICAM)-2 regulates angiogenesis.
148	WPLICR01	Anna Randi	Tool, Cell line	MCEC KO ICAM2
149	WPLICR01	Anna Randi	Tool, Cell line	MCEC KOICAM2-pBabe
150	WPLICR02	Buzz Baum	training activities	Training in post-genomic biology
151	WPLICR02	Buzz Baum	training activities	EMBO course
152	WPLICR02	Buzz Baum	Tool, Transgenic animal	GFP flies for in vivo RNAi
153	WPLICR02	Buzz Baum	scientific publications	Review article
154	WPLICR02	Buzz Baum	Tool, other	2 hybrid analysis initiated
155	WPLICR02	Buzz Baum	Tool, Interfering RNA	Human siRNA library for silencing actin regulators.

156	WPLICR02	Buzz Baum	Tool, Software	FLIGHT
157	WPLICR05	Marketa Zvelebil	Tool, Software	PHAT
158	WPLICR05	Marketa Zvelebil	scientific publications	pSTIING: a systems approach towards integrating signalling pathways
159	WPLICR05	Marketa Zvelebil	Tool, Software	Protein Interaction knowledgebase
160	WPLICR05	Marketa Zvelebil	Tool, Software	Main Resources: Deliverable database
161	WPLICR05	Marketa Zvelebil	Tool, Software	Main Resources: Deliverable database
162	WPLICR05	Marketa Zvelebil	Tool, Software	Main Resources: Tool database
163	WPLICR05	Marketa Zvelebil	scientific meetings/workshops	Bioinformatics tutorial
164	WPLICR05	Marketa Zvelebil	Tool, Tutorial	Using MAIN, FLIGHT and pSTIING database
165	WPLICR05	Marketa Zvelebil	scientific publications	FLIGHT
166	WPLICR05	Marketa Zvelebil	scientific publications	Resources for integrative systems biology: From data through databases to networks and dynamic system models
167	WPLICR20	Anne Ridley	Tool, Transgenic animal	Mice lacking functional p110beta in monocytes/macrophages
168	WPLICR20	Anne Ridley	scientific publications	Role of RhoA in p110delta signalling
169	WPLICR20	Anne Ridley	Tool, Transgenic animal	Mice with constitutive inactive p110beta
170	WPLICR20	Anne Ridley	Tool, Antibody	antibodies to p110beta
171	WPLMU05	Fritz Krombach	scientific publications	Postischemic vascular permeability requires both TLR-2 and TLR-4 but only TLR-2 mediates the transendothelial migration of leukocytes
172	WPLMU05	Fritz Krombach	scientific publications	An orally active chemokine receptor CCR-1 antagonist improves advanced nephropathy in type 2 diabetic db/db mice by blocking interstitial macrophages
173	WPLMU05	Fritz Krombach	scientific publications	Matrix metalloproteinases 2 and 9 promote neutrophil and T cell migration in the postischemic liver
174	WPLMU05	Fritz Krombach	scientific publications	Chemokine receptors Ccr1, Ccr2, and Ccr5 mediate neutrophil migration to postischemic tissue
175	WPLMU05	Fritz Krombach	scientific publications	CD4+ T cells interacting with sinusoidal endothelium and platelets

				aggravate microvascular hepatic ischemia-reperfusion injury via CD40-CD40L- and ...
176	WPLMU05	Hans-Joachim Anders	scientific publications	Disease mechanisms of glomerulonephritis: chemokines and chemokine receptors.
177	WPLMU05	Hans-Joachim Anders	scientific publications	Chemokines as therapeutic targets in renal disease: Lessons from antagonist studies and knock out mice.
178	WPLMU05	Hans-Joachim Anders	scientific publications	CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome.
179	WPLMU05	Hans-Joachim Anders	scientific publications	Progression of kidney disease: blocking leukocyte recruitment with chemokine receptor CCR1 antagonists.
180	WPLMU05	Hans-Joachim Anders	scientific publications	Molecular mechanisms of autoimmunity triggered by microbial infection.
181	WPLMU05	Hans-Joachim Anders	scientific publications	Progression of kidney disease: blocking leukocyte recruitment with chemokine receptor CCR1 antagonists.
182	WPLMU05	Hans-Joachim Anders	scientific publications	Molecular mechanisms of autoimmunity triggered by microbial infection.
183	WPLMU05	Hans-Joachim Anders	scientific publications	Current paradigms about chemokines as therapeutic targets
184	WPLMU05	Hans-Joachim Anders	scientific publications	Toll-like receptor-7 modulates immune complex glomerulonephritis.
185	WPLMU05	Hans-Joachim Anders	scientific publications	Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells.
186	WPLMU05	Hans-Joachim Anders	scientific publications	Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease.
187	WPLMU05	Hans-Joachim Anders	scientific publications	G-Rich DNA Suppresses Systemic Lupus
188	WPLMU05	Hans-Joachim Anders	scientific publications	Toll-like receptor-4: renal cells and bone marrow cells signal for neutrophil recruitment during pyelonephritis
189	WPLMU05	Hans-Joachim Anders	scientific publications	Crucial role of chemokine receptors for neutrophil migration in postischemic tissue in vivo
190	WPLMU05	Hans-Joachim	scientific publications	Targeting the chemokine network in renal inflammation.

		Anders		
191	WPLMU06	Judith P. Johnson	Tools	CD146 (MCAM) -/- mice on C57BL/6 and Balb/c backgrounds
192	WPLMU06	Judith P. Johnson	Tool, cDNA	human CD146 (MCAM) lacking cytoplasmic region; in pcDNA3
193	WPLMU06	Judith P. Johnson	Tool, Promoter	Human ICAM-1 luciferase reporter constructs
194	WPLMU06	Judith P. Johnson	Tool, Antibody	Monoclonal anti human CD146 induces signal transduction M18MAD-5D7
195	WPLMU06	Judith P. Johnson	Tool, Antibody	Anti-human MCAM/CD146 monoclonal AB MUC18 IgG2a
196	WPLMU06	Judith P. Johnson	Tool, cDNA	human MCAM full length cDNA (wildtype) in pcDNA3
197	WPLMU06	Judith P. Johnson	Tool, Protocol/assay	in vivo angiogenesis assay: the matrigel plug assay
198	WPLMU06	Judith P. Johnson	Tool, Promoter	human MCAM/CD146 promoter luciferase reporter constructs in pXp2
199	WPLMU06	Judith P. Johnson	Tool, Antibody	Monoclonal anti human ICAM-1 western blot
200	WPLMU06	Judith P. Johnson	Tool, Cell line	human SBCl2 melanoma cells stably transfected with MCAM/CD146
201	WPLMU06	Judith P. Johnson	Tool, Protocol/assay	in vivo angiogenesis assay: the matrigel plug assay
202	WPLMU06	Judith P. Johnson	Tool, Promoter	human MCAM/CD146 promoter luciferase reporter constructs in pXp2
203	WPLMU06	Judith P. Johnson	Tool, Antibody	Monoclonal anti human ICAM-1 western blot
204	WPLMU06	Judith P. Johnson	Tool, Cell line	human SBCl2 melanoma cells stably transfected with MCAM/CD146
205	WPLMU06	Judith P. Johnson	Tool, Cell line	Human melanoma cells Mel888 stably transfected with MCAM/CD146 cDNA
206	WPLMU06	Judith P.	Tool, Cell line	coloncarcinoma Colo320 stably transfected with MCAM/CD146

		Johnson		
207	WPLMU06	Judith P. Johnson	Tool, Protocol/assay	endothelial tubule formation in vitro
208	WPLMU06	Judith P. Johnson	Tool, Antibody	Monoclonal anti human CD146 (MCAM) western blot
209	WPLMU06	Judith P. Johnson	Tool, Cell line	293 cells stably transfected with human MCAM/CD146
210	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Plasmid	Cyt-pcDNA3/-eGFP/monomeric eGFPΔVCAM-1-
211	WPUAMAD01	Francisco Sánchez-Madrid	scientific publications	Association of MT1-MMP with tetraspanin CD151 at endothelial lateral junctions regulates its enzymatic activity
212	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Plasmid	ICAM-1-GFP
213	WPUAMAD01	Francisco Sánchez-Madrid	scientific publications	Endothelial tetraspanin microdomains regulate leukocyte firm adhesion during extravasation.
214	WPUAMAD01	Francisco Sánchez-Madrid	scientific publications	EWI-2 and EWI-F link the tetraspanin web to the actin cytoskeleton through their direct association with ezrin-radixin-moesin proteins.
215	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Plasmid	VCAM-1-pcDNA3/CFP/YFP/mRFP/monomeric eGFP
216	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Plasmid	CD151-GFP
217	WPUAMAD01	Francisco Sánchez-Madrid	scientific meetings/workshops	Participation in 1st MAIN Annual meeting
218	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Plasmid	CD9-CFP/YFP/mRFP/monomeric eGFP
219	WPUAMAD01	Francisco Sánchez-Madrid	scientific meetings/workshops	Participation in 1st MAIN PhD students retreat
220	WPUAMAD01	Francisco Sánchez-Madrid	scientific meetings/workshops	Participation in 2nd MAIN PhD students retreat
221	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Interfering RNA	CD151 siRNA
222	WPUAMAD01	Francisco	Tool, Plasmid	ICAM-1-pcDNA3/CFP/YFP/mRFP/monomeric eGFP

		Sánchez-Madrid		
223	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Plasmid	CD81-GFP
224	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Interfering RNA	CD9 siRNA
225	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Plasmid	CD9-GFP
226	WPUAMAD01	Francisco Sánchez-Madrid	scientific publications	Endothelial tetraspanin microdomains regulate leukocyte firm adhesion during extravasation.
227	WPUAMAD01	Francisco Sánchez-Madrid	scientific publications	EWI-2 and EWI-F link the tetraspanin web to the actin cytoskeleton through their direct association with ezrin-radixin-moesin proteins.
228	WPUAMAD01	Francisco Sánchez-Madrid	Tool, Plasmid	VCAM-1-pcDNA3/CFP/YFP/mRFP/monomeric eGFP
229	WPUAMAD02	Ivan de Curtis	Tool, Interfering RNA	Small interfering RNAs to study the effects of GIT1
230	WPUAMAD02	Ivan de Curtis	Tool, Plasmid	Plasmids for the expression in eukaryotes to test the interaction with GRK2
231	WPUAMAD02	Ivan de Curtis	Tool, Interfering RNA	Small interfering RNAs to study the effects of bPIX
232	WPUAMAD02	Ivan de Curtis	Tool, Plasmid	Plasmid pEGFP-p95-C
233	WPUAMAD02	Ivan de Curtis	Tool, Antibody	Polyclonal antibody specific for GIT proteins
234	WPUAMAD02	Federico Mayor Menéndez	scientific publications	G protein -coupled receptor kinase 2
235	WPUAMAD02	Federico Mayor Menéndez	Tool, Antibody	FP1-Ab and FP2-Ab
236	WPUAMAD02	Federico Mayor Menéndez	scientific publications	Myosin II is involved in ligand-induced internalization of the chemokine receptor CXCR4
237	WPUAMAD02	Federico Mayor Menéndez	Tool, Cell line	Hela and Cos
238	WPUAMAD02	Federico Mayor Menéndez	training activities	Training in signal transduction imaging and cell migration-related methodologies
239	WPUAMAD02	Federico Mayor Menéndez	scientific publications	Modulation of the interaction between GRK2 and GIT-1

240	WPUAMAD02	Federico Mayor Menéndez	Tool, Plasmid	GRK2
241	WPUAMAD02	Federico Mayor Menéndez	Tool, Interfering RNA	MIIA siRNA
242	WPUAMAD02	Federico Mayor Menéndez	Tool, Plasmid	GIT-1
243	WPUAMAD02	Federico Mayor Menéndez	scientific meetings/workshops	Participation in 1st MAIN PhD students retreat
244	WPUAMAD02	Federico Mayor Menéndez	Tool, Plasmid	MIIA tail-GFP
245	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	TP1/40 Mouse mAb anti-human alphaL integrin (CD11a)
246	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	LIA1/1 Mouse mAb anti-human CD151
247	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	VJ1/16 Mouse mAb anti-human CD151
248	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	TEA1/41 Mouse mAb, anti-human alpha2 integrin (CD49b).
249	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	RP1/12 Mouse mAb, anti-human CD45RC.
250	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	D3/9 Mouse mAb, anti-human CD45.
251	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	LIA3/2 Mouse mAb anti-human beta-2 integrin (CD18)
252	WPUAMAD03	Francisco Sánchez-Madrid	training activities	Training of a technician in the growth, production and testing of mAbs
253	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	HP2/4 Mouse mAb, anti-human alpha 4 integrin (CD49d)
254	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	HP2/19 Mouse mAb anti-human ICAM-3 (CD50)
255	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	VJ1/6 Mouse mAb, anti-human alpha3 integrin (CD49c).

256	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	HC1/1-B5 Mouse mAb, anti-human Integrin alphaX (CD11c)
257	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	TEA3/9 Mouse mAb, anti-human E-Selectin (CD65E).
258	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	RP1/11 Mouse mAb, anti-human CD45RA
259	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	HP1/7 Mouse mAb, anti-human alpha 4 integrin (CD49d)
260	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	TP1/55 Mouse mAb anti-human CD69
261	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	TP1/55 Mouse mAb anti-human CD69
262	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	HP2/1 Mouse mAb, anti-human alpha 4 integrin (CD49d)
263	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	TEA1/31 Mouse mAb, anti-human VE-Cadherin.
264	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	RP2/21 Mouse mAb, anti-human CD45RB
265	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	VJ1/10 Mouse mAb, anti-human CD9.
266	WPUAMAD03	Francisco Sánchez-Madrid	Tool, Antibody	TP1/15 Mouse mAb, anti-human CD31.
267	WPUAMAD04	Manuel Ortíz de Landázuri	Tool, Interfering RNA	siRNAαHIF-1
268	WPUAMAD04	Manuel Ortíz de Landázuri	scientific publications	Role of the hypoxia in the macrophage activation.
269	WPUAMAD04	Manuel Ortíz de Landázuri	scientific meetings/workshops	Participation in 1st MAIN PhD students retreat
270	WPUAMAD04	Manuel Ortíz de Landázuri	scientific publications	Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene.
271	WPUAMAD04	Manuel Ortíz de	Tool, Protocol/assay	Chromatine Immunoprecipitation (ChIP), used to determine binds to

		Landázuri		or is localized to a specific DNA sequence in vivo.αwhether HIF-1
272	WPUAMAD04	Manuel Ortíz de Landázuri	scientific publications	Analysis of HIF-prolyl hydroxylases binding to substrates
273	WPUAMAD04	Manuel Ortíz de Landázuri	Tool, Interfering RNA	PHD3 siRNA
274	WPUAMAD04	Manuel Ortíz de Landázuri	scientific meetings/workshops	Participation in 2nd MAIN PhD students retreat
275	WPUAMAD04	Manuel Ortíz de Landázuri	Tool, Interfering RNA	PHD2 siRNA
276	WPUAMAD04	Manuel Ortíz de Landázuri	scientific publications	von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-in
277	WPUAMAD04	Manuel Ortíz de Landázuri	scientific publications	Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene
278	WPUAMAD04	Manuel Ortíz de Landázuri	scientific meetings/workshops	Participation in 2nd MAIN Annual meeting
279	WPUAMAD04	Manuel Ortíz de Landázuri	training activities	Training of postdoctoral fellow and PhD students in signal transduction, imaging and cell migration-related methodologies
280	WPUAMAD04	Manuel Ortíz de Landázuri	scientific publications	Activation of HIF-prolyl hydrosilases by R59949, an inhibitor of the diacylglicerol kinase
281	WPUAMAD04	Manuel Ortíz de Landázuri	scientific publications	Activation of HIF-prolyl hydrosilases by R59949, an inhibitor of the diacylglicerol kinase
282	WPUAMAD04	Manuel Ortíz de Landázuri	scientific publications	Von Hippel-Lindau Tumor Supressor Protein Regulates the Assembly of Intercellular Junctions in Renal Cancer Cells through Hypoxia-Inducible Factor-Ind
283	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Expression and function of the nuclear factor of activated T cells in colon carcinoma cells: involvement in the regulation of cyclooxygenase-2.
284	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Up-regulation of G Protein-Coupled Receptor Kinase 2 during T cell activation: A potential role in the control of CXCR4 expression
285	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Up-regulation of cyclooxygenase-2 by interleukin-1? in colon carcinoma cells.

286	WPUAMAD05	Manuel Fresno Escudero	Tool, Interfering RNA	Development, application and transfer to other MAIN participant groups of siRNA technique on primary leukocytes.
287	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Up-regulation of cyclooxygenase-2 by interleukin-1β in colon carcinoma cells.
288	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Peroxisome proliferator-activated receptor alpha agonists inhibit cyclooxygenase 2 and vascular endothelial growth factor transcriptional activation i
289	WPUAMAD05	Manuel Fresno Escudero	patents	Possible therapeutic applications in inflammation and tumor migration.
290	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Involvement of TNF and NF-kappa B in the transcriptional control of cyclooxygenase-2 expression by IFN-gamma in macrophages
291	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Expression and function of the nuclear factor of activated T cells in colon carcinoma cells: involvement in the regulation of cyclooxygenase-2.
292	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Up-regulation of G Protein-Coupled Receptor Kinase 2 during T cell activation: A potential role in the control of CXCR4 expression. .
293	WPUAMAD05	Manuel Fresno Escudero	patents	Possible therapeutic applications in inflammation and tumor migration
294	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Involvement of TNF and NF-kappa B in the transcriptional control of cyclooxygenase-2 expression by IFN-gamma in macrophages.
295	WPUAMAD05	Manuel Fresno Escudero	Tool, Cell line	Genetically modified cell lines (Jurkat T COX-2 Tet-on, Jurkat T PGDS Tet-on, THP-1 COX-2 siRNA, THP-1 mPGES-1 siRNA)
296	WPUAMAD05	Manuel Fresno Escudero	Tools	Genetically modified cell lines
297	WPUAMAD05	Manuel Fresno Escudero	training activities	Training on migration techniques
298	WPUAMAD05	Manuel Fresno Escudero	Tools	Development, application and transfer to other MAIN participant groups of siRNA technique on primary leukocytes
299	WPUAMAD05	Manuel Fresno Escudero	Tool, Cell line	Jurkat Tet-on inducible cell line stably transfected with human hematopoietic Prostaglandin D synthase cDNA
300	WPUAMAD05	Manuel Fresno Escudero	scientific publications	Peroxisome proliferator-activated receptor alpha agonists inhibit cyclooxygenase 2 and vascular endothelial growth factor transcriptional activation i

301	WPUAMAD05	Bernhard Moser	training activities	Training of Alicia Hidalgo
302	WPUAMAD06	Manuel Fresno Escudero	Tool, cDNA	Human COX-2 Expression plasmid
303	WPUAMAD06	Manuel Fresno Escudero	Tool, Promoter	Mouse Cyclooxygenase-2 promoter deletions and mutants in pxP2 luciferase reporter vector
304	WPUAMAD06	Manuel Fresno Escudero	Tool, cDNA	Human Cyclooxygenase-2 expression plasmid
305	WPUAMAD06	Manuel Fresno Escudero	Tools	Creation of a cDNA expression plasmid repository bank and catalogue
306	WPUAMAD06	Manuel Fresno Escudero	Tool, Promoter	iNOS promoter
307	WPUAMAD06	Manuel Fresno Escudero	Tools	Creation of a cDNA expression plasmid repository bank and catalogue
308	WPUAMAD06	Manuel Fresno Escudero	Tool, Plasmid	GAL4-cRel constructs
309	WPUAMAD06	Manuel Fresno Escudero	Tool, Plasmid	GAL4-NFAT constructs
310	WPUAMAD06	Manuel Fresno Escudero	Tool, Plasmid	GAL4-NFATc2 chimeric constructs including deletions of the transactivation domain of human NFATc2
311	WPUAMAD06	Manuel Fresno Escudero	Tool, Plasmid	GAL4-cRel chimeric constructs including deletions of the transactivation domain of c-Rel NF?B
312	WPUAMAD06	Manuel Fresno Escudero	Tool, Promoter	iNOS promoter deletions and mutants in pxP2 and pGL3 luciferase reporter vector
313	WPUAMAD06	Manuel Fresno Escudero	Tool, Promoter	Human COX-2 promoter
314	WPUAMAD06	Manuel Fresno Escudero	Tool, Promoter	Mouse Cyclooxygenase-2 promoter deletions and mutants in pxP2 luciferase reporter vector
315	WPUAMAD06	Manuel Fresno Escudero	Tool, Promoter	mouse COX-2 promoter
316	WPUAMAD06	Manuel Fresno Escudero	Tool, Plasmid	GAL4-NFATc2 chimeric constructs including deletions of the transactivation domain of human NFATc2
317	WPUAMAD20	Ivan de Curtis	Tool, Interfering RNA	siRNA for rat GIT2 in RBL cells

318	WPUAMAD20	Ivan de Curtis	Tool, Interfering RNA	siRNA for rat PIX proteins in RBL cells
319	WPUAMAD20	Ivan de Curtis	Tool, Interfering RNA	siRNA for rat GIT1 in RBL cells
320	WPUAMAD20	Federico Mayor Menéndez	scientific publications	
321	WPUAMAD20	Federico Mayor Menéndez	scientific publications	Mdm2 is involved in the ubiquitination and degradation of G protein-coupled receptor kinase 2
322	WPUAMAD20	Federico Mayor Menéndez	scientific publications	Myosin IIA is involved in ligand-induced endocytosis of the chemokine receptor CXCR4.
323	WPUAMAD20	Federico Mayor Menéndez	training activities	
324	WPUAMAD20	Federico Mayor Menéndez	Tools	
325	WPUAMAD20	Federico Mayor Menéndez	Tools	
326	WPUAMAD20	Federico Mayor Menéndez	Tool, Antibody	
327	WPUAMAD31	Ruggero Pardi	Tool, Plasmid	b2 arrestin Hu 6His P90,92A
328	WPUAMAD31	Ruggero Pardi	Tool, Plasmid	b2 arrestin Hu 6His
329	WPUAMAD31	Ruggero Pardi	Tool, Plasmid	b1 arrestin Hu 6His P89,91A
330	WPUAMAD31	Ruggero Pardi	Tool, Protocol/assay	Rap1 in vitro activation assay
331	WPUAMAD31	Ruggero Pardi	scientific publications	Pathophysiology of leukocyte-tissue interactions.
332	WPUAMAD31	Ruggero Pardi	Tool, Plasmid	b2 arrestin Hu 6His P90,92,95,98A
333	WPUAMAD31	Ruggero Pardi	Tool, Plasmid	b2 arrestin Hu 6His P95,98A
334	WPUAMAD31	Ruggero Pardi	Tool, Plasmid	RalGDS-RBD GST
335	WPUAMAD31	Ruggero Pardi	Tool, Plasmid	b1 arrestin Hu 6His
336	WPUMUEN01	Volker Gerke	Tool, Antibody	Antibodies directed against monocyte gene products
337	WPUMUEN01	Volker Gerke	scientific publications	Identification of monocyte gene products
338	WPUMUEN01	Volker Gerke	Tool, Interfering RNA	RNA interference tools to knock-down monocyte gene products
339	WPUMUEN01	Volker Gerke	Tool, Interfering RNA	siRNA duplexes and constructs to knock-down monocyte gene

				products
340	WPUMUEN02	Dietmar Vestweber	Tool, Tutorial	Leukocyte cell adhesion and migration assays
341	WPUMUEN02	Dietmar Vestweber	scientific publications	physiological functions of ESAM as deduced from the analysis of ESAM -/- mice
342	WPUMUEN02	Dietmar Vestweber	scientific publications	ESAM supports neutrophil extravasation, activation of Rho, and VEGF-induced vascular permeability
343	WPUMUEN02	Dietmar Vestweber	Tool, Tutorial	purification of mouse leukocytes
344	WPUMUEN02	Dietmar Vestweber	Tool, Transgenic animal	ESAM deficient mice
345	WPUMUEN02	Dietmar Vestweber	Tool, Cell line	ESAM deficient mouse endothelioma cell lines
346	WPUMUEN02	Dietmar Vestweber	Tool, Antibody	monoclonal antibodies against mouse ESAM
347	WPUMUEN02	Dietmar Vestweber	scientific publications	A CD99-related antigen on endothelial cells mediates neutrophil, but not lymphocyte extravasation in vivo
348	WPUMUEN02	Dietmar Vestweber	Tools	Antibodies directed against endothelial cell contact proteins and the corresponding cDNAs
349	WPUMUEN02	Fritz Krombach	scientific publications	Leukocyte transmigration in inflamed liver: A role for endothelial cell-selective adhesion molecule
350	WPUMUEN02	Fritz Krombach	Other	Technology for the in vivo study of thrombus formation
351	WPUMUEN03	Stephan Grabbe	training activities	Training for purification of murine primary T and B cells
352	WPUMUEN03	Stephan Grabbe	scientific publications	Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral blood leukocyte depletion
353	WPUMUEN03	Stephan Grabbe	Tool, Transgenic animal	OVA-expressing B16 tumor cell line
354	WPUMUEN03	Stephan Grabbe	Tool, Protocol/assay	Purification of murine primary T cells and B cells from spleen and lymph node
355	WPUNIBAS01	Matthias P. Wymann	Tool, Plasmid	shRNA expression plasmids, inducible

356	WPWEIZMANN05	Francoise Cailler Group	scientific publications	See JI (2005) 174:3227-3236
357	WPWeizmann01	Steffen Jung	Other	DC and macrophage precursors
358	WPWeizmann02	Idit Shachar	Tools	Data set of differentially expressed genes in B and T cells following maturation and activation
359	WPWeizmann02	Idit Shachar	scientific publications	Tight regulation of IFN-g transcription and secretion in immature and mature B cells by the inhibitory MHC class I receptor, Ly49G2
360	WPWeizmann02	Idit Shachar	scientific publications	Expression of the Chemokine Receptor CCR2 on Immature B cells
361	WPWeizmann02	Idit Shachar	Tools	Transgenic animal- CD19-YFP transgenic mice
362	WPWeizmann04	Ronen Alon	scientific publications	Alpha4beta1-dependent adhesion strengthening under mechanical strain is regulated by paxillin association with the alpha4 cytoplasmic domain
363	WPWeizmann04	Ronen Alon	scientific publications	Lymphocyte arrest on endothelial ICAM-1
364	WPWeizmann04, WPWeizmann05	Ronen Alon	scientific publications	Force as a facilitator of integrin conformational changes during leukocyte arrest on blood vessels and antigen-presenting cells
365	WPWeizmann04, WPWeizmann06	Ronen Alon	scientific publications	Immune cell migration in inflammation
366	WPWeizmann04; WPWeizmann05	Ronen Alon	Tool, Tutorial	Flow chamber techniques and analyses
367	WPWeizmann04; WPWeizmann05; WPWeizmann06	Ronen Alon	Tool, Tutorial	Leukocyte purification
368	WPWeizmann05	Ofer Lider	scientific publications	Enzymattically quiescent heparanase augments T cell interactions with VCAM-1 and extracellular matrix components under versatile dynamic contexts
369	WPWeizmann05	Ofer Lider	scientific publications	Heat shock protein 60 inhibits Th1-mediated hepatitis model via innat regulation of Th1/Th2 transcription factors and cytokines
370	WPWeizmann05	Ofer Lider	scientific publications	Heat shock protein 60 activates cytokine-associated negative regulator suppressor of cytokine signaling 3 in T cells: effects on signaling, chemotaxis
371	Weizmann01	Steffen Jung	training activities	Isolation and Adoptive Transfer of Mononuclear Phagocyte Precursors

372	wPUAMAD06	Manuel Fresno Escudero	Tool, Promoter	Human Cyclooxygenase-2 promoter deletions and mutants in pxP2 luciferase reporter vector
373	wPUAMAD06	Manuel Fresno Escudero	Tool, Promoter	Human Cyclooxygenase-2 promoter deletions and mutants in pxP2 luciferase reporter vector
374	wpifom20	Giorgio Scita	Tool, Transgenic animal	Molecular mechanisms controlling and coordinating the activities of WASP
375	wpifom20	Giorgio Scita	Tool, Plasmid	Molecular mechanisms controlling and coordinating the activities of WASP
376	wpifom20	Giorgio Scita	Tool, Antibody	Molecular mechanisms controlling and coordinating the activities of WASP
377	wpifom20	Giorgio Scita	Tool, Antibody	Molecular mechanisms controlling and coordinating the activities of WASP
378	wpifom20	Giorgio Scita	Tool, Transgenic animal	Molecular mechanisms controlling and coordinating the activities of WASP
379	wpifom20	Giorgio Scita	Tool, Interfering RNA	Molecular mechanisms controlling and coordinating the activities of WASP
380	wpifom20	Giorgio Scita	Tool, Transgenic animal	Molecular mechanisms controlling and coordinating the activities of WASP
381		Bernhard Moser	scientific publications	Constitutive expression of CXCL14 in healthy human and murine epithelial tissues
382		Bernhard Moser	scientific publications	A rapid crosstalk of human gd T cells and monocytes drives the acute inflammation in bacterial infections
383		Marlene Wolf	scientific publications	Proteolytic processing of chemokines: Implications in physiological and pathological conditions
384		Marlene Wolf	scientific publications	Potent and Broad-Spectrum Antimicrobial Activity of CXCL14 Suggests an Immediate Role in Skin Infections
385		Matthias P. Wymann	Tool, Tutorial	PI3K signaling in immune cells
386		Anna Randi		
387		Anna Randi		
388		Anna Randi	Tool, Antibody	

389		Anna Randi		
390		Anna Randi	Other	
391		Anna Randi	Tool, Antibody	
392		Anna Randi		

Report on the Distribution of the Community's contribution

Type of Instrument	NOE	Project Title (or Acronym)	MAIN	Contract N°	LSHG-CT-2003-502935

Part I — Community's prefinancing (or payment) sent to the coordinator (1)

	Reporting Period 1 (2)		Reporting Period 2 (2)		Reporting Period 3 (2)		Reporting Period 4 (2)		Reporting Period 5 (2)		Reporting Period 6 (2)		Reporting Period 7 (2)		Final payment		Total Amount (I) (3)
	From	To	From	To	From	To	From	To	From	To	From	To	From	To			
	1-01-2004	31-12-2004	1-01-2005	31-12-2005	1-01-2006	31-12-2006	1-01-2007	31-12-2007	1-01-2008	31-12-2008							
	Date	Amount (A)	Date	Amount (B)	Date	Amount (C)	Date	Amount (D)	Date	Amount (E)	Date	Amount (F)	Date	Amount (G)	Date	Amount (H)	
Total (X)	25-03-2004	4.800.000,00	19-08-2005	1.307.530,03	29-12-2006	1.763.016,74	27-11-2007	845.232,87	18-09-2008	621.248,50							9.337.028,14

Part II — Distribution of the Community's prefinancing (or payment) between contractors according to the consortium decision(s) (4)

Contractor n°	Organisation Short Name	Country Code	Reporting Period 1		Reporting Period 2		Reporting Period 3		Reporting Period 4		Reporting Period 5		Reporting Period 6		Reporting Period 7		Final payment		Total Amount (I') (6)
			Date(s) (5)	Amount(s) (A') (5)	Date(s) (5)	Amount(s) (B') (5)	Date(s) (5)	Amount(s) (C') (5)	Date(s) (5)	Amount(s) (D') (5)	Date(s) (5)	Amount(s) (E') (5)	Date(s) (5)	Amount(s) (F') (5)	Date(s) (5)	Amount(s) (G') (5)	Date(s) (5)	Amount(s) (H') (5)	
1	FCSR	I	23-04-2004	591.900,00	7-06-2005	156.544,00	14-06-2006	3.600,00	2-02-2007	309.480,00	8-10-2008	129.486,86							1.191.010,86
					23-09-2005	147.709,00			31-12-2007	213.269,00									360.978,00
					25-10-2005	269.400,00													269.400,00
																			0,00
			Total	591.900,00	Total	573.653,00	Total	3.600,00	Total	522.749,00	Total	129.486,86	Total	0,00	Total	0,00	Total	0,00	1.821.388,86
2	UAMAD	E	23-04-2004	346.400,00	7-06-2005	152.000,00	14-06-2006	3.600,00	5-02-2007	204.605,51	2-01-2008	107.070,00							813.675,51
					23-09-2005	68.800,00					9-10-2008	116.442,91							185.242,91
					25-10-2005	71.400,00													71.400,00
																			0,00
			Total	346.400,00	Total	292.200,00	Total	3.600,00	Total	204.605,51	Total	223.512,91	Total	0,00	Total	0,00	Total	0,00	1.070.318,42
3	LICR	GB	23-04-2004	484.397,00	7-06-2005	341.416,00	14-06-2006	3.600,00	5-02-2007	293.339,85									1.122.752,85
					23-09-2005	97.083,00			28-12-2007	10.240,00									107.323,00
					25-10-2005	145.800,00													145.800,00
																			0,00
			Total	484.397,00	Total	584.299,00	Total	3.600,00	Total	303.579,85	Total	0,00	Total	0,00	Total	0,00	Total	0,00	1.375.875,85
4	UMUEN	D	23-04-2004	299.400,00	7-06-2005	118.400,00	14-06-2006	3.600,00	5-02-2007	138.919,68									560.319,68
					23-09-2005	33.280,00			25-05-2007	152.760,00									186.040,00
					25-10-2005	128.400,00													128.400,00
																			0,00
			Total	299.400,00	Total	280.080,00	Total	3.600,00	Total	291.679,68	Total	0,00	Total	0,00	Total	0,00	Total	0,00	874.759,68
5	EMBL	D	23-04-2004	113.686,00	7-06-2005	40.320,00	14-06-2006	3.600,00	2-02-2007	31.980,00	2-01-2008	61.020,00							250.606,00
					23-09-2005	9.864,00					9-10-2008	9.577,97							19.441,97
					25-10-2005	56.400,00													56.400,00
																			0,00
			Total	113.686,00	Total	106.584,00	Total	3.600,00	Total	31.980,00	Total	70.597,97	Total	0,00	Total	0,00	Total	0,00	326.447,97
6	IFOM	I	23-04-2004	291.566,67	7-06-2005	111.180,00	14-06-2006	3.600,00	2-02-2007	179.556,00	8-10-2008	113.804,70							699.707,37
					23-09-2005	60.636,00			24-12-2007	88.740,00									149.376,00
					25-10-2005	68.400,00													68.400,00
																			0,00
			Total	291.566,67	Total	240.216,00	Total	3.600,00	Total	268.296,00	Total	113.804,70	Total	0,00	Total	0,00	Total	0,00	917.483,37
7	IRB	CH																	0,00
																			0,00
																			0,00
																			0,00
			Total	0,00	Total	0,00	Total	0,00	Total	0,00	Total	0,00	Total	0,00	Total	0,00	Total	0,00	0,00
8	TKI	CH																	0,00
																			0,00
																			0,00
																			0,00
			Total	0,00	Total	0,00	Total	0,00	Total	0,00	Total	0,00	Total	0,00	Total	0,00	Total	0,00	0,00

9	LMU	D	23-04-2004	342.940,00	7-06-2005	170.000,00	14-06-2006	3.600,00	5-02-2007	291.756,06									808.296,06
					23-09-2005	52.000,00			4-04-2007	-152.676,90									-100.676,90
																			0,00
																			0,00
			Total	342.940,00	Total	222.000,00	Total	3.600,00	Total	139.079,16	Total	0,00	Total	0,00	Total	0,00	Total	0,00	707.619,16
10	Weizmann	IL	23-04-2004	267.757,84	7-06-2005	94.604,00	14-06-2006	3.600,00	5-02-2007	218.179,29	9-10-2008	99.470,87							683.612,00
					23-09-2005	66.921,00			28-12-2007	26.820,66									93.741,66
																			0,00
																			0,00
			Total	267.757,84	Total	161.525,00	Total	3.600,00	Total	244.999,95	Total	99.470,87	Total	0,00	Total	0,00	Total	0,00	777.353,66

Page n° /	1	2

Report on the Distribution of the Community's contribution

Type of Instrument	NOE	Project Title (or Acronym)	MAIN	Contract N°	LSHG-CT-2003-502935

Part II — Distribution of the Community's prefinancing (or payment) between contractors according to the consortium decision(s) *(4)*

Contractor n°	Organisation Short Name	Country Code	Reporting Period 1		Reporting Period 2		Reporting Period 3		Reporting Period 4		Reporting Period 5		Reporting Period 6		Reporting Period 7		Final payment		Total Amount (I') *(6)*
			Date(s) *(5)*	Amount(s) (A') *(5)*	Date(s) *(5)*	Amount(s) (B') *(5)*	Date(s) *(5)*	Amount(s) (C') *(5)*	Date(s) *(5)*	Amount(s) (D') *(5)*	Date(s) *(5)*	Amount(s) (E') *(5)*	Date(s) *(5)*	Amount(s) (F') *(5)*	Date(s) *(5)*	Amount(s) (G') *(5)*	Date(s) *(5)*	Amount(s) (H') *(5)*	
11	IMP COLL	GB	23-04-2004	162.416,00	7-06-2005	101.402,00	14-06-2006	3.600,00	5-02-2007	76.946,71	9-10-2008	83.009,53							427.374,24
					23-09-2005	28.680,00			28-12-2007	85.518,99									114.198,99
					25-10-2005	16.710,00													16.710,00
																			0,00
			Total	162.416,00	Total	146.792,00	Total	3.600,00	Total	162.465,70	Total	83.009,53	Total	0,00	Total	0,00	Total	0,00	558.283,23
12	UNIBAS	CH																	0,00
																			0,00
																			0,00
																			0,00
			Total	0,00	Total	0,00	Total	0,00	Total	0,00	Total	0,00	Total	0,00	Total	0,00	Total	0,00	0,00
13	IPBS-CNRS	F	23-04-2004	80.000,00	7-06-2005	34.000,00	14-06-2006	3.600,00	2-02-2007	15.600,00	9-10-2008	19.602,80							152.802,80
					23-09-2005	23.600,00													23.600,00
																			0,00
																			0,00
			Total	80.000,00	Total	57.600,00	Total	3.600,00	Total	15.600,00	Total	19.602,80	Total	0,00	Total	0,00	Total	0,00	176.402,80
14	BXL	I	23-04-2004	96.132,82	7-06-2005	50.944,00	14-06-2006	3.600,00	31-12-2007	3.037,00									153.713,82
					23-09-2005	16.189,00													16.189,00
																			0,00
																			0,00
			Total	96.132,82	Total	67.133,00	Total	3.600,00	Total	3.037,00	Total	0,00	Total	0,00	Total	0,00	Total	0,00	169.902,82
15	ENDOCUBE	F	23-04-2004	76.000,00	7-06-2005	15.300,00	14-06-2006	3.060,00	28-12-2007	32.160,00									126.520,00
							28-12-2006	53.000,00											53.000,00
																			0,00
																			0,00
			Total	76.000,00	Total	15.300,00	Total	56.060,00	Total	32.160,00	Total	0,00	Total	0,00	Total	0,00	Total	0,00	179.520,00
16	SPR	I							18-05-2007	15.338,70									15.338,70
																			0,00
																			0,00
																			0,00
			Total	0,00	Total	0,00	Total	0,00	Total	15.338,70	Total	0,00	Total	0,00	Total	0,00	Total	0,00	15.338,70
17	AXXAM	I							31-12-2007	51.991,00									51.991,00
																			0,00
																			0,00
																			0,00
			Total	0,00	Total	0,00	Total	0,00	Total	51.991,00	Total	0,00	Total	0,00	Total	0,00	Total	0,00	51.991,00
18	ICR	UK									11-09-2008	14.040,00							14.040,00
																			0,00
																			0,00
																			0,00
			Total	0,00	Total	0,00	Total	0,00	Total	0,00	Total	14.040,00	Total	0,00	Total	0,00	Total	0,00	14.040,00
19	KCL	UK									9-10-2008	179.059,94							179.059,94
																			0,00
																			0,00
																			0,00
			Total	0,00	Total	0,00	Total	0,00	Total	0,00	Total	179.059,94	Total	0,00	Total	0,00	Total	0,00	179.059,94

20	QM	UK									9-10-2008	92.103,26						92.103,26
																		0,00
																		0,00
																		0,00
			Total	0,00	Total	0,00	Total	0,00	Total	0,00	Total	92.103,26	Total	0,00	Total	0,00	Total	0,00	92.103,26
21	UCL	UK									11-09-2008	48.690,00						48.690,00
																		0,00
																		0,00
																		0,00
			Total	0,00	Total	0,00	Total	0,00	Total	0,00	Total	48.690,00	Total	0,00	Total	0,00	Total	0,00	48.690,00
Total (Y)			Total	3.152.596,33	Total	2.747.382,00	Total	95.660,00	Total	2.287.561,55	Total	1.073.378,84	Total	0,00	Total	0,00	Total	0,00	9.356.578,72

Part III	Difference between Community's prefinancing (or payment) sent to the coordinator and Total Distribution of the Community's prefinancing (or payment) between contractors according to the consortium decision(s) *(4)*								
	Reporting Period 1	Reporting Period 2	Reporting Period 3	Reporting Period 4	Reporting Period 5	Reporting Period 6	Reporting Period 7	Final payment	Total Amount
Community's prefinancing (or payment) not yet distributed between contractors (Z) *(7)*	1.647.403,67	-1.439.851,97	1.667.356,74	-1.442.328,68	-452.130,34	0,00	0,00	0,00	-19.550,58

I certify that the information set out in this(these) form(s) is accurate and correct and agreed by all contractors.

Name *(8)*	Surname *(8)*	Date (dd/mm/yyyy)	Signature of the administrative official authorised to commit the organisation of the coordinator *(8)*
Rag. Mario	Valsecchi	25-02-2009	

Explanatory notes

(1): To be filled in only by the Commission services.
(2): Established in conformity with articles 4.2 and 6 of the contract.
(3): (I) = (A) + (B) + (C) + (D) + (E) + (F) + (G) + (H)
(4): To be filled in only by the coordinator.
(5): Insert the dates (dd/mm/yyyy) and the amounts (x,xxx.xx €) transferred to a contractor (including the coordinator) for a reporting period. If there are more than one transfer to a contractor during a reporting period, identify each date and each relating transferred amount.
(6): (I') = (A') + (B') + (C') + (D') + (E') + (F') + (G') + (H')
(7): (Z) = (X) - (Y)
(8): One the following persons : authorised contact person or first or second administrative official authorised to sign the contract, as mentioned in your Contract Preparation Form (Form A2b)